☰

Terri S. Armstrong, Ph.D., N.P. - Publications

Affiliations: 
1996-2000 Neurosurgery Winship Cancer Institue, Emory University 
 2000-2016 Neuro-Oncology M.D. Anderson Cancer Center, Houston, TX, United States 
 2003-2016 School of Nursing University of Texas, Health Science Center at Houston 
 2016- Neuro-Oncology Branch CCR, NCI, NIH 
Area:
symptom assessment, management, myelotoxicity
Website:
https://nursing.uth.edu/directory/profile/index.htm?profileinode=f1040d2a-3e1a-472f-9171-479f7af0f4dc
Tree Info Grants Similar researchers PubMed Report error

258 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Kim Y, Armstrong TS, Gilbert MR, Celiku O. Disparities in the availability and access to Neuro-Oncology Trial-Supporting infrastructure in the United States. Journal of the National Cancer Institute. PMID 39325856 DOI: 10.1093/jnci/djae240  0.366
2024 Pascoe MM, Wollet AR, De La Cruz Minyety J, Vera E, Miller H, Celiku O, Leeper H, Fernandez K, Reyes J, Young D, Acquaye-Mallory A, Adegbesan K, Boris L, Burton E, Chambers CP, ... ... Armstrong TS, et al. Assessing sleep in primary brain tumor patients using smart wearables and patient-reported data: Feasibility and interim analysis of an observational study. Neuro-Oncology Practice. 11: 640-651. PMID 39279778 DOI: 10.1093/nop/npae048  0.783
2024 Obrecht-Sturm D, Schoof M, Eckhardt A, Mynarek M, Gilbert MR, Aldape K, Armstrong TS, Ramaswamy V, Bockmayr M, von Hoff K, Fleischhack G, Adolph JE, Tippelt S, Pfister SM, Pajtler K, et al. Distinct relapse pattern across molecular ependymoma types. Neuro-Oncology. PMID 39171767 DOI: 10.1093/neuonc/noae166  0.306
2024 Acquaye-Mallory A, Vera E, Choi A, Wall K, Gilbert MR, Armstrong TS. Identifying associations between sample characteristics, symptoms, and self-efficacy differences in adult patients with rare tumors of the central nervous system who participated in a novel web-based natural history study. Cancer Medicine. 13: e70017. PMID 39101481 DOI: 10.1002/cam4.70017  0.432
2024 Stockdill ML, King A, Johnson M, Karim Z, Cooper D, Armstrong TS. The relationship between social determinants of health and neurocognitive and mood-related symptoms in the primary brain tumor population: A systematic review. Neuro-Oncology Practice. 11: 226-239. PMID 38737608 DOI: 10.1093/nop/npae016  0.664
2024 Price M, Neff C, Nagarajan N, Kruchko C, Waite KA, Cioffi G, Cordeiro BB, Willmarth N, Penas-Prado M, Gilbert MR, Armstrong TS, Barnholtz-Sloan JS, Ostrom QT. CBTRUS Statistical Report: American Brain Tumor Association & NCI Neuro-Oncology Branch Adolescent and Young Adult Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2016-2020. Neuro-Oncology. 26: iii1-iii53. PMID 38709657 DOI: 10.1093/neuonc/noae047  0.465
2024 Rogers JL, Wall T, Acquaye-Mallory AA, Boris L, Kim Y, Aldape K, Quezado MM, Butman JA, Smirniotopoulos JG, Chaudhry H, Tsien CI, Chittiboina P, Zaghloul K, Aboud O, Avgeropoulos NG, ... ... Armstrong TS, et al. Virtual multi-institutional tumor board: a strategy for personalized diagnoses and management of rare CNS tumors. Journal of Neuro-Oncology. PMID 38427131 DOI: 10.1007/s11060-024-04613-6  0.449
2024 Briceno N, Vera E, Komlodi-Pasztor E, Abdullaev Z, Choi A, Grajkowska E, Kunst T, Levine J, Lindsley M, Fernandez K, Reyes J, Boris L, Burton E, Panzer M, Polskin L, ... ... Armstrong TS, et al. Long-term survivors of glioblastoma: Tumor molecular, clinical, and imaging findings. Neuro-Oncology Advances. 6: vdae019. PMID 38420614 DOI: 10.1093/noajnl/vdae019  0.419
2023 Li A, Hancock JC, Quezado M, Ahn S, Briceno N, Celiku O, Ranjan S, Aboud O, Colwell N, Kim SA, Nduom E, Kuhn S, Park DM, Vera E, Aldape K, ... Armstrong TS, et al. TGF-β and BMP signaling are associated with the transformation of glioblastoma to gliosarcoma and then osteosarcoma. Neuro-Oncology Advances. 6: vdad164. PMID 38292240 DOI: 10.1093/noajnl/vdad164  0.364
2023 Byrne EM, Pascoe M, Cooper D, Armstrong TS, Gilbert MR. Challenges and limitations of clinical trials in the adolescent and young adult CNS cancer population: A systematic review. Neuro-Oncology Advances. 6: vdad159. PMID 38250563 DOI: 10.1093/noajnl/vdad159  0.394
2023 Cherng HR, Sun K, Bentzen S, Armstrong TS, Gondi V, Brown PD, Mehta M, Mishra MV. Evaluating the Heterogeneity of Hippocampal Avoidant Whole Brain Radiotherapy Treatment Effect: A Secondary Analysis of NRG CC001. Neuro-Oncology. PMID 38069666 DOI: 10.1093/neuonc/noad226  0.347
2023 Price M, Neff C, Kruchko C, Barnholtz-Sloan JS, Cordeiro BB, Penas-Prado M, Ozer BH, Cimino PJ, Gilbert MR, Armstrong TS, Ostrom QT. Capturing evolving definitions of 12 select rare CNS tumors: a timely report from CBTRUS and NCI-CONNECT. Journal of Neuro-Oncology. 165: 279-290. PMID 37980692 DOI: 10.1007/s11060-023-04480-7  0.464
2023 Adegbesan KA, Tomassoni Ardori F, Yanpallewar S, Bradley SP, Chudasama Y, Vera E, Briceno N, King AL, Tessarollo L, Gilbert MR, Guedes VA, Smart DK, Armstrong TS, Shuboni-Mulligan DD. The sex-dependent impact of PER2 polymorphism on sleep and activity in a novel mouse model of cranial-irradiation-induced hypersomnolence. Neuro-Oncology Advances. 5: vdad108. PMID 37781088 DOI: 10.1093/noajnl/vdad108  0.789
2023 Kim Y, Gilbert MR, Armstrong TS, Celiku O. Clinical outcome assessment trends in clinical trials-Contrasting oncology and non-oncology trials. Cancer Medicine. PMID 37421295 DOI: 10.1002/cam4.6325  0.42
2023 Gondi V, Deshmukh S, Brown PD, Wefel JS, Armstrong TS, Tome WA, Gilbert MR, Konski A, Robinson CG, Bovi JA, Benzinger TLS, Roberge D, Kundapur V, Kaufman I, Shah S, et al. Sustained Preservation of Cognition and Prevention of Patient-Reported Symptoms with Hippocampal Avoidance during Whole-Brain Radiotherapy for Brain Metastases: Final Results of NRG Oncology CC001. International Journal of Radiation Oncology, Biology, Physics. PMID 37150264 DOI: 10.1016/j.ijrobp.2023.04.030  0.442
2023 King AL, Acquaye-Mallory AA, Vera E, Mendoza T, Reyes J, Stockdill ML, Gilbert MR, Armstrong TS. Feasibility and preliminary efficacy of a virtual reality intervention targeting distress and anxiety in primary brain tumor patients at the time of clinical evaluation: Study protocol for a phase 2 clinical trial. Bmc Cancer. 23: 262. PMID 36944930 DOI: 10.1186/s12885-023-10671-2  0.745
2023 King AL, Roche KN, Leeper HE, Vera E, Mendoza T, Mentges K, Acquaye-Mallory AA, Adegbesan KA, Boris L, Burton E, Choi A, Grajkowska E, Kunst T, Levine J, Lollo N, ... ... Armstrong TS, et al. Feasibility of a virtual reality intervention targeting distress and anxiety symptoms in patients with primary brain tumors: Interim analysis of a phase 2 clinical trial. Journal of Neuro-Oncology. PMID 36884201 DOI: 10.1007/s11060-023-04271-0  0.741
2023 King AL, Acquaye AA, Mendoza T, Reyes J, Stockdill M, Gilbert MR, Armstrong TS, Vera E. Feasibility and preliminary efficacy of a virtual reality intervention targeting distress and anxiety in primary brain tumor patients at the time of clinical evaluation: Study protocol for a phase 2 clinical trial. Research Square. PMID 36865245 DOI: 10.21203/rs.3.rs-2521990/v1  0.729
2023 King AL, Roche KN, Leeper HE, Vera E, Mendoza T, Mentges K, Acquaye AA, Adegbesan K, Boris L, Burton E, Choi A, Grajkowska E, Kunst T, Levine J, Lollo N, ... ... Armstrong TS, et al. Feasibility of a virtual reality intervention targeting distress and anxiety symptoms in patients with primary brain tumors: Interim analysis of a phase 2 clinical trial. Research Square. PMID 36789426 DOI: 10.21203/rs.3.rs-2522094/v1  0.731
2023 Kim Y, Armstrong TS, Gilbert MR, Celiku O. A Critical Analysis of Neuro-Oncology Clinical Trials. Neuro-Oncology. PMID 36757281 DOI: 10.1093/neuonc/noad036  0.359
2023 Leeper HE, Vera E, Christ A, Acquaye A, Briceno N, Choi A, Grajkowska E, Jammula V, Levine J, Lindsley M, Reyes J, Roche KN, Rogers JL, Timmer M, Boris L, ... ... Armstrong TS, et al. Association of Employment Status With Symptom Burden and Health-Related Quality of Life in People Living With Primary CNS Tumors. Neurology. PMID 36754634 DOI: 10.1212/WNL.0000000000207082  0.505
2023 Frederico SC, Vera E, Abdullaev Z, Acquaye A, Aldape K, Boris L, Briceno N, Choi A, Christ A, Cooper D, Grajkowska E, Kunst T, Leeper HE, Levine J, Lollo N, ... ... Armstrong TS, et al. Heterogeneous clinicopathological findings and patient-reported outcomes in adults with -altered CNS tumors: A case report and systematic literature review. Frontiers in Oncology. 13: 1099618. PMID 36741001 DOI: 10.3389/fonc.2023.1099618  0.494
2023 Jenkins S, Zhang W, Steinberg SM, Nousome D, Houston N, Wu X, Armstrong TS, Burton E, Smart D, Shah R, Peer CJ, Mozarsky B, Arisa O, Figg WD, Mendoza TR, et al. Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 36705597 DOI: 10.1158/1078-0432.CCR-22-0855  0.361
2023 Liu Y, Chou FJ, Lang F, Zhang M, Song H, Zhang W, Davis DL, Briceno NJ, Zhang Y, Cimino PJ, Zaghloul KA, Gilbert MR, Armstrong TS, Yang C. Protein kinase B (PKB/AKT) protects IDH-mutated glioma from ferroptosis via Nrf2. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 36648507 DOI: 10.1158/1078-0432.CCR-22-3179  0.311
2023 Roche KN, Cooper D, Armstrong TS, King AL. The link between psychological distress and survival in solid tumor patients: A systematic review. Cancer Medicine. PMID 36602400 DOI: 10.1002/cam4.5200  0.704
2022 Bergsneider BH, Vera E, Gal O, Christ A, King AL, Acquaye A, Choi A, Leeper HE, Mendoza T, Boris L, Burton E, Lollo N, Panzer M, Penas-Prado M, Pillai T, ... ... Armstrong TS, et al. Discovery of clinical and demographic determinants of symptom burden in primary brain tumor patients using network analysis and unsupervised clustering. Neuro-Oncology Advances. 5: vdac188. PMID 36820236 DOI: 10.1093/noajnl/vdac188  0.733
2022 King AL, Shuboni-Mulligan DD, Vera E, Crandon S, Acquaye AA, Boris L, Burton E, Choi A, Christ A, Grajkowska E, Jammula V, Leeper HE, Lollo N, Penas-Prado M, Reyes J, ... ... Armstrong TS, et al. Exploring the prevalence and burden of sleep disturbance in primary brain tumor patients. Neuro-Oncology Practice. 9: 526-535. PMID 36388423 DOI: 10.1093/nop/npac049  0.813
2022 Vera E, Christ A, Grajkowska E, Briceno N, Choi A, Crandon SK, Wall K, Lindsley M, Leeper HE, Levine J, Reyes J, Acquaye AA, King AL, Jammula V, Roche K, ... ... Armstrong TS, et al. Relationship between RANO-PRO Working Group standardised priority constructs and disease progression among malignant glioma patients: A retrospective cohort study. Eclinicalmedicine. 55: 101718. PMID 36386035 DOI: 10.1016/j.eclinm.2022.101718  0.717
2022 Ruiz-Rodado V, Dowdy T, Lita A, Kramp T, Zhang M, Shuboni-Mulligan D, Herold-Mende C, Armstrong TS, Gilbert MR, Camphausen K, Larion M. Metabolic biomarkers of radiotherapy response in plasma and tissue of an IDH1 mutant astrocytoma mouse model. Frontiers in Oncology. 12: 979537. PMID 36353533 DOI: 10.3389/fonc.2022.979537  0.766
2022 Scheurer ME, Zhou R, Gilbert MR, Bondy ML, Sulman EP, Yuan Y, Liu Y, Vera E, Wendland MM, Youssef EF, Stieber VW, Komaki RR, Flickinger JC, Kenyon LC, Robins HI, ... ... Armstrong TS, et al. Germline polymorphisms in associated with temozolomide-related myelotoxicity risk in patients with glioblastoma treated on NRG Oncology/RTOG 0825. Neuro-Oncology Advances. 4: vdac152. PMID 36299794 DOI: 10.1093/noajnl/vdac152  0.416
2022 Jammula V, Rogers JL, Vera E, Christ A, Leeper HE, Acquaye A, Briceno N, Choi A, Grajkowska E, Levine JE, Lindsley M, Reyes J, Roche KN, Timmer M, Boris L, ... ... Armstrong TS, et al. The Montreal Cognitive Assessment (MoCA) in neuro-oncology: A pilot study of feasibility and utility in telehealth and in-person clinical assessments. Neuro-Oncology Practice. 9: 429-440. PMID 36124322 DOI: 10.1093/nop/npac038  0.371
2022 Sass D, Vera E, Choi A, Acquaye A, Briceno N, Christ A, Grajkowska E, Jammula V, Levine J, Lindsley M, Reyes J, Roche K, Rogers JL, Timmer M, Boris L, ... ... Armstrong TS, et al. Evaluation of the key geriatric assessment constructs in primary brain tumor population - a descriptive study. Journal of Geriatric Oncology. PMID 36041994 DOI: 10.1016/j.jgo.2022.08.013  0.42
2022 Merchant M, Raygada M, Pang Y, Quezado M, Raffeld M, Xi L, Kim J, Tyagi M, Abdullaev Z, Kim O, Sergi Z, Pillai T, Ozer B, Zaghloul K, Heiss JD, ... Armstrong TS, et al. Case report: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, associated with a germline mutation in . Frontiers in Oncology. 12: 954879. PMID 35982947 DOI: 10.3389/fonc.2022.954879  0.4
2022 Lassman AB, Pugh SL, Wang TJC, Aldape K, Gan HK, Preusser M, Vogelbaum MA, Sulman EP, Won M, Zhang P, Moazami G, Macsai MS, Gilbert MR, Bain EE, Blot V, ... ... Armstrong TS, et al. Depatuxizumab-mafodotin in EGFR-amplified newly diagnosed glioblastoma: a phase III randomized clinical trial. Neuro-Oncology. PMID 35849035 DOI: 10.1093/neuonc/noac173  0.309
2022 Shuboni-Mulligan DD, Young D, De La Cruz Minyety J, Briceno N, Celiku O, King AL, Munasinghe J, Wang H, Adegbesan KA, Gilbert MR, Smart DK, Armstrong TS. Histological analysis of sleep and circadian brain circuitry in cranial radiation-induced hypersomnolence (C-RIH) mouse model. Scientific Reports. 12: 11131. PMID 35778467 DOI: 10.1038/s41598-022-15074-0  0.784
2022 Woodford R, Prather L, Helfer C, Davey L, Penas-Prado M, Armstrong T, Tucker K, Aldape K, Gilbert M, Clark C, Thavaneswaran S, Wang D, Mandel J, Kasherman L. Malignant melanocytic schwannian tumor and leptomeningeal disease: A case series with a focus on management. Journal of the Neurological Sciences. 438: 120291. PMID 35635863 DOI: 10.1016/j.jns.2022.120291  0.392
2022 Rogers JL, De La Cruz Minyety J, Vera E, Acquaye AA, Payén SS, Weinberg JS, Armstrong TS, Weathers SS. Assessing mobility in primary brain tumor patients: A descriptive feasibility study using two established mobility tests. Neuro-Oncology Practice. 9: 219-228. PMID 35601968 DOI: 10.1093/nop/npac013  0.301
2022 Komlodi-Pasztor E, Gilbert MR, Armstrong TS. Diagnosis and Management of Stroke in Adults with Primary Brain Tumor. Current Oncology Reports. PMID 35543860 DOI: 10.1007/s11912-022-01280-6  0.429
2022 Leeper HE, Tonorezos E, Mayer D, Bakitas M, Chang S, Cooley ME, Hervey-Jumper S, Miaskowski C, Sherwood P, Tsien C, Wallgren K, Willmarth N, Arons D, Acquaye A, King AL, ... ... Armstrong TS, et al. Proceedings of the Survivorship Care in Neuro-Oncology Workshop sponsored by the Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT). Neuro-Oncology Advances. 4: vdac029. PMID 35542753 DOI: 10.1093/noajnl/vdac029  0.68
2022 Rabin EE, Kim M, Mozny A, Cardoza K, Bell AC, Zhai L, Bommi P, Lauing KL, King AL, Armstrong TS, Walunas TL, Fang D, Roy I, Peipert JD, Sieg E, et al. A systematic review of pharmacologic treatment efficacy for depression in older patients with cancer. Brain, Behavior, & Immunity - Health. 21: 100449. PMID 35368609 DOI: 10.1016/j.bbih.2022.100449  0.631
2022 Pratt D, Abdullaev Z, Papanicolau-Sengos A, Ketchum C, Panneer Selvam P, Chung HJ, Lee I, Raffeld M, Gilbert MR, Armstrong TS, Pytel P, Borys E, Klonoski JM, McCord M, Horbinski C, et al. High-grade glioma with pleomorphic and pseudopapillary features (HPAP): a proposed type of circumscribed glioma in adults harboring frequent TP53 mutations and recurrent monosomy 13. Acta Neuropathologica. PMID 35103816 DOI: 10.1007/s00401-022-02404-9  0.429
2021 Walker JG, Armstrong TS, O'Brien BJ, Gilbert MR, Casarez RL, Fagundes C, Heijnen CJ, Andersen CR, Yuan Y, Wu J, LoBiondo-Wood G. Associations of meaning of illness with psychosocial, clinical, and immunological characteristics in patients with Leptomeningeal metastasis. Comprehensive Psychoneuroendocrinology. 8: 100099. PMID 35757676 DOI: 10.1016/j.cpnec.2021.100099  0.695
2021 Yu G, Pang Y, Merchant M, Kesserwan C, Gangalapudi V, Abdelmaksoud A, Ranjan A, Kim O, Wei JS, Chou HC, Wen X, Sindiri S, Song YK, Xi L, Kaplan RN, ... Armstrong TS, et al. Tumor Mutation Burden, Expressed Neoantigens and the Immune Microenvironment in Diffuse Gliomas. Cancers. 13. PMID 34885201 DOI: 10.3390/cancers13236092  0.403
2021 Armstrong TS, Gilbert MR. Clinical trial challenges, design considerations, and outcome measures in rare CNS tumors. Neuro-Oncology. 23: S30-S38. PMID 34725696 DOI: 10.1093/neuonc/noab209  0.436
2021 Noll K, King AL, Dirven L, Armstrong TS, Taphoorn MJB, Wefel JS. Neurocognition and Health-Related Quality of Life Among Patients with Brain Tumors. Hematology/Oncology Clinics of North America. 36: 269-282. PMID 34711455 DOI: 10.1016/j.hoc.2021.08.011  0.688
2021 Jammula VR, Leeper H, Gilbert MR, Cooper D, Armstrong TS. Effects of Cognitive Reserve on Cognition in Individuals With Central Nervous System Disease. Cognitive and Behavioral Neurology : Official Journal of the Society For Behavioral and Cognitive Neurology. PMID 34508028 DOI: 10.1097/WNN.0000000000000282  0.35
2021 Pang Y, Yu G, Butler M, Sindiri S, Song YK, Wei JS, Wen X, Chou HC, Quezado M, Pack S, Xi L, Abdullaev Z, Kim O, Ranjan A, Merchant M, ... ... Armstrong TS, et al. Report of Canonical - Fusion in Glioblastoma. Jco Precision Oncology. 5. PMID 34485806 DOI: 10.1200/PO.20.00519  0.316
2021 Sievers P, Henneken SC, Blume C, Sill M, Schrimpf D, Stichel D, Okonechnikov K, Reuss DE, Benzel J, Maaß KK, Kool M, Sturm D, Zheng T, Ghasemi DR, Kohlhof-Meinecke P, ... ... Armstrong TS, et al. Recurrent fusions in PLAGL1 define a distinct subset of pediatric-type supratentorial neuroepithelial tumors. Acta Neuropathologica. PMID 34355256 DOI: 10.1007/s00401-021-02356-6  0.46
2021 Al Feghali KA, Randall JW, Liu DD, Wefel JS, Brown PD, Grosshans DR, McAvoy SA, Farhat MA, Li J, McGovern SL, McAleer MF, Ghia AJ, Paulino AC, Sulman EP, Penas-Prado M, ... ... Armstrong TS, et al. Phase II trial of proton therapy versus photon IMRT for GBM: secondary analysis comparison of progression-free survival between RANO versus clinical assessment. Neuro-Oncology Advances. 3: vdab073. PMID 34337411 DOI: 10.1093/noajnl/vdab073  0.401
2021 Rogers JL, Vera E, Acquaye A, Briceno N, Jammula V, King AL, Leeper H, Quezado MM, Gonzalez Alarcon J, Boris L, Burton E, Celiku O, Choi A, Christ A, Crandon S, ... ... Armstrong TS, et al. Living with a central nervous system (CNS) tumor: findings on long-term survivorship from the NIH Natural History Study. Neuro-Oncology Practice. 8: 460-474. PMID 34277024 DOI: 10.1093/nop/npab022  0.719
2021 Rogers JL, Vera E, Acquaye A, Briceno N, Jammula V, King AL, Leeper H, Quezado MM, Gonzalez Alarcon J, Boris L, Burton E, Celiku O, Choi A, Christ A, Crandon S, ... ... Armstrong TS, et al. Living with a central nervous system (CNS) tumor: findings on long-term survivorship from the NIH Natural History Study. Neuro-Oncology Practice. 8: 460-474. PMID 34277024 DOI: 10.1093/nop/npab022  0.304
2021 Dirven L, Vos ME, Walbert T, Armstrong TS, Arons D, van den Bent MJ, Blakeley J, Brown PD, Bulbeck H, Chang SM, Coens C, Gilbert MR, Grant R, Jalali R, Leach D, et al. Systematic review on the use of patient-reported outcome measures in brain tumor studies: part of the Response Assessment in Neuro-Oncology Patient-Reported Outcome (RANO-PRO) initiative. Neuro-Oncology Practice. 8: 417-425. PMID 34277020 DOI: 10.1093/nop/npab013  0.483
2021 Dirven L, Vos ME, Walbert T, Armstrong TS, Arons D, van den Bent MJ, Blakeley J, Brown PD, Bulbeck H, Chang SM, Coens C, Gilbert MR, Grant R, Jalali R, Leach D, et al. Systematic review on the use of patient-reported outcome measures in brain tumor studies: part of the Response Assessment in Neuro-Oncology Patient-Reported Outcome (RANO-PRO) initiative. Neuro-Oncology Practice. 8: 417-425. PMID 34277020 DOI: 10.1093/nop/npab013  0.319
2021 De La Cruz Minyety J, Shuboni-Mulligan DD, Briceno N, Young D, Gilbert MR, Celiku O, Armstrong TS. Association of Circadian Clock Gene Expression with Glioma Tumor Microenvironment and Patient Survival. Cancers. 13. PMID 34199348 DOI: 10.3390/cancers13112756  0.745
2021 De La Cruz Minyety J, Shuboni-Mulligan DD, Briceno N, Young D, Gilbert MR, Celiku O, Armstrong TS. Association of Circadian Clock Gene Expression with Glioma Tumor Microenvironment and Patient Survival. Cancers. 13. PMID 34199348 DOI: 10.3390/cancers13112756  0.745
2021 Shuboni-Mulligan DD, Young DL, De La Cruz Minyety J, Vera E, Munasinghe J, Gall AJ, Gilbert MR, Armstrong TS, Smart DK. Impact of age on the circadian visual system and the sleep-wake cycle in mus musculus. Npj Aging and Mechanisms of Disease. 7: 10. PMID 33947857 DOI: 10.1038/s41514-021-00063-w  0.731
2021 Piil K, Whisenant M, Mendoza T, Armstrong T, Cleeland C, Nordentoft S, Williams LA, Jarden M. Psychometric validity and reliability of the Danish version of the MD Anderson Symptom Inventory Brain Tumor Module. Neuro-Oncology Practice. 8: 137-147. PMID 33898047 DOI: 10.1093/nop/npaa068  0.363
2021 Wu J, Yuan Y, Long Priel DA, Fink D, Peer CJ, Sissung TM, Su YT, Pang Y, Yu G, Butler MK, Mendoza TR, Vera E, Ahmad S, Bryla C, Lindsley M, ... ... Armstrong TS, et al. Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33785481 DOI: 10.1158/1078-0432.CCR-20-4730  0.4
2021 Brown PD, Chung C, Liu DD, McAvoy S, Grosshans D, Al Feghali K, Mahajan A, Li J, McGovern SL, McAleer MF, Ghia AJ, Sulman EP, Penas-Prado M, de Groot JF, Heimberger AB, ... ... Armstrong TS, et al. A Prospective Phase II Randomized Trial of Proton Radiotherapy vs. Intensity Modulated Radiotherapy for Patients with Newly Diagnosed Glioblastoma. Neuro-Oncology. PMID 33647972 DOI: 10.1093/neuonc/noab040  0.39
2021 Wefel JS, Armstrong TS, Pugh SL, Gilbert MR, Wendland MM, Brachman DG, Roof KS, Brown PD, Crocker IR, Robins HI, Hunter G, Won M, Mehta MP. Neurocognitive, Symptom, and Health- Related Quality of Life Outcomes of a Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma (NRG/RTOG 0825). Neuro-Oncology. PMID 33515019 DOI: 10.1093/neuonc/noab011  0.438
2020 Yu G, Butler MK, Abdelmaksoud A, Pang Y, Su YT, Rae Z, Dadkhah K, Kelly MC, Song YK, Wei JS, Terabe M, Atony R, Mentges K, Theeler BJ, Penas-Prado M, ... ... Armstrong TS, et al. Case Report: Single-Cell Transcriptomic Analysis of an Anaplastic Oligodendroglioma Post Immunotherapy. Frontiers in Oncology. 10: 601452. PMID 33520712 DOI: 10.3389/fonc.2020.601452  0.487
2020 Penas-Prado M, Wu J, Cahill DP, Brat DJ, Costello JF, Kluetz PG, Cairncross JG, van den Bent M, Verhaak RGW, Aboud O, Burger P, Chang SM, Cordova C, Huang RY, Rowe LS, ... ... Armstrong TS, et al. Proceedings of the Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT) Oligodendroglioma Workshop. Neuro-Oncology Advances. 2: vdz048. PMID 33289010 DOI: 10.1093/noajnl/vdz048  0.466
2020 Penas-Prado M, Armstrong TS, Gilbert MR. Proposed Additions to the NCCN Guidelines for Adult Medulloblastoma. Journal of the National Comprehensive Cancer Network : Jnccn. 18: 1579-1584. PMID 33152706 DOI: 10.6004/jnccn.2020.7650  0.491
2020 Gilbert MR, Yuan Y, Wu J, Mendoza T, Vera E, Omuro A, Lieberman F, Robins HI, Gerstner ER, Wu J, Wen PY, Mikkelsen T, Aldape K, Armstrong TS. A Phase II Study of Dose-Dense Temozolomide and Lapatinib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma. Neuro-Oncology. PMID 33085768 DOI: 10.1093/neuonc/noaa240  0.397
2020 Leggiero NM, Armstrong TS, Gilbert MR, King AL. Use of virtual reality for symptom management in solid-tumor patients with implications for primary brain tumor research: a systematic review. Neuro-Oncology Practice. 7: 477-489. PMID 33014388 DOI: 10.1093/Nop/Npaa012  0.764
2020 Penas-Prado M, Theeler BJ, Cordeiro B, Dunkel IJ, Hau P, Mahajan A, Robinson GW, Willmarth N, Aboud O, Aldape K, Butman JA, Gajjar A, Kelly W, Rao G, Raygada M, ... ... Armstrong TS, et al. Proceedings of the Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT) Adult Medulloblastoma Workshop. Neuro-Oncology Advances. 2: vdaa097. PMID 33005896 DOI: 10.1093/noajnl/vdaa097  0.421
2020 Lynes J, Acquaye AA, Sur H, Nwankwo A, Sanchez V, Vera E, Wu T, Theeler B, Armstrong TS, Gilbert MR, Nduom EK. Variations in attitudes towards stereotactic biopsy of adult diffuse midline glioma patients: a survey of members of the AANS/CNS Tumor Section. Journal of Neuro-Oncology. PMID 32705457 DOI: 10.1007/S11060-020-03585-7  0.477
2020 Theeler BJ, Dalal Y, Monje M, Shilatifard A, Suvà ML, Aboud O, Camphausen K, Cordova C, Finch E, Heiss JD, Packer RJ, Romo CG, Aldape K, Penas-Prado M, Armstrong T, et al. NCI-CONNECT: Comprehensive Oncology Network Evaluating Rare CNS Tumors-Histone Mutated Midline Glioma Workshop Proceedings. Neuro-Oncology Advances. 2: vdaa007. PMID 32642676 DOI: 10.1093/noajnl/vdaa007  0.432
2020 Raffeld M, Abdullaev Z, Pack SD, Xi L, Nagaraj S, Briceno N, Vera E, Pittaluga S, Lopes Abath Neto O, Quezado M, Aldape K, Armstrong TS, Gilbert MR. High level MYCN amplification and distinct methylation signature define an aggressive subtype of spinal cord ependymoma. Acta Neuropathologica Communications. 8: 101. PMID 32641156 DOI: 10.1186/S40478-020-00973-Y  0.437
2020 Hui D, De La Rosa A, Wilson A, Nguyen T, Wu J, Delgado-Guay M, Azhar A, Arthur J, Epner D, Haider A, De La Cruz M, Heung Y, Tanco K, Dalal S, Reddy A, ... ... Armstrong TS, et al. Neuroleptic strategies for terminal agitation in patients with cancer and delirium at an acute palliative care unit: a single-centre, double-blind, parallel-group, randomised trial. The Lancet. Oncology. PMID 32479786 DOI: 10.1016/S1470-2045(20)30307-7  0.321
2020 Armstrong TS, Chang SM, Jenkinson D, Kluetz P, Taphoorn MJB. Glioma patient-reported outcome assessment in clinical care - Authors' reply. The Lancet. Oncology. 21: e231. PMID 32359496 DOI: 10.1016/S1470-2045(20)30241-2  0.345
2020 Penas-Prado M, Armstrong TS, Gilbert MR. Letter to the Editor Re: Mohile et al. Neuro-Oncology. PMID 32343803 DOI: 10.1093/Neuonc/Noaa109  0.344
2020 Tanaka S, Sato I, Takahashi M, Armstrong TS, Cleeland CS, Mendoza TR, Mukasa A, Takayanagi S, Narita Y, Kamibeppu K, Saito N. Validation study of the Japanese version of MD Anderson Symptom Inventory for Brain Tumor module. Japanese Journal of Clinical Oncology. PMID 32280995 DOI: 10.1093/Jjco/Hyaa036  0.447
2020 Zimmer AS, Steinberg SM, Smart DD, Gilbert MR, Armstrong TS, Burton E, Houston N, Biassou N, Gril B, Brastianos PK, Carter S, Lyden D, Lipkowitz S, Steeg PS. Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases. Future Oncology (London, England). PMID 32270710 DOI: 10.2217/Fon-2020-0094  0.405
2020 Rogers JL, Acquaye A, Vera E, Bates A, Wen PY, Armstrong TS. Provider-reported challenges and barriers to referring patients to neuro-oncology clinical trials: a report from the Society for Neuro-Oncology member survey. Neuro-Oncology Practice. 7: 38-51. PMID 32257283 DOI: 10.1093/Nop/Npz038  0.336
2020 Puduvalli VK, Wu J, Yuan Y, Armstrong TS, Vera E, Wu J, Xu J, Giglio P, Colman H, Walbert T, Raizer J, Groves MD, Tran D, Iwamoto F, Avgeropoulos N, et al. A Bayesian Adaptive Randomized Phase II Multicenter Trial of Bevacizumab with or without Vorinostat in Adults with Recurrent Glioblastoma. Neuro-Oncology. PMID 32166308 DOI: 10.1093/Neuonc/Noaa062  0.373
2020 Rowe L, Vera E, Acquaye A, Crandon S, Shah V, Bryla C, Wu J, Wall K, Siegel C, Reyes J, Penas-Prado M, Leggiero N, Cordova C, Burton E, Antony R, ... ... Armstrong T, et al. The prevalence of altered body image in patients with primary brain tumors: an understudied population. Journal of Neuro-Oncology. PMID 32096067 DOI: 10.1007/S11060-020-03433-8  0.546
2020 Brown PD, Gondi V, Pugh S, Tome WA, Wefel JS, Armstrong TS, Bovi JA, Robinson C, Konski A, Khuntia D, Grosshans D, Benzinger TLS, Bruner D, Gilbert MR, Roberge D, et al. Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1902767. PMID 32058845 DOI: 10.1200/Jco.19.02767  0.473
2020 Armstrong TS, Dirven L, Arons D, Bates A, Chang SM, Coens C, Espinasse C, Gilbert MR, Jenkinson D, Kluetz P, Mendoza T, Rubinstein L, Sul J, Weller M, Wen PY, et al. Glioma patient-reported outcome assessment in clinical care and research: a Response Assessment in Neuro-Oncology collaborative report. The Lancet. Oncology. 21: e97-e103. PMID 32007210 DOI: 10.1016/S1470-2045(19)30796-X  0.52
2020 Theeler BJ, Jung J, Burton E, Gonzalez J, Leeper H, Wu J, Nduom E, Zaghloul K, Ray-Chaudhury A, Quezado M, Raffeld M, Allen JE, Prabhu VV, Stogniew M, Oster W, ... ... Armstrong T, et al. A first-in-human phase I single-agent dose-escalation, food effect and dose expansion study of oral ONC206 in recurrent and rare primary central nervous system neoplasms. Journal of Clinical Oncology. 38. DOI: 10.1200/Jco.2020.38.15_Suppl.Tps2576  0.407
2019 Yust-Katz S, O'Brien B, Vera E, Acquaye A, Weller M, Armstrong T. Burnout and Career Satisfaction in Neuro-Oncology: A Survey of the Society for Neuro-Oncology and the European Association of Neuro-Oncology Membership. Neuro-Oncology. PMID 31832657 DOI: 10.1093/Neuonc/Noz229  0.352
2019 Robins HI, Eickhoff J, Gilbert MR, Armstrong TS, Shi W, De Groot JF, Schultz CJ, Hunter GK, Valeinis E, Roach M, Youssef EF, Souhami L, Howard SP, Lieberman FS, Herman JG, et al. The association between BMI and BSA-temozolomide-induced myelosuppression toxicities: a correlative analysis of NRG oncology RTOG 0525. Neuro-Oncology Practice. 6: 473-478. PMID 31832217 DOI: 10.1093/Nop/Npz006  0.336
2019 Shuboni-Mulligan DD, Breton G, Smart D, Gilbert M, Armstrong TS. Radiation chronotherapy-clinical impact of treatment time-of-day: a systematic review. Journal of Neuro-Oncology. PMID 31729636 DOI: 10.1007/S11060-019-03332-7  0.779
2019 Penas-Prado M, Armstrong TS, Gilbert MR. Progress in rare central nervous system tumors. Current Opinion in Neurology. PMID 31577601 DOI: 10.1097/Wco.0000000000000755  0.457
2019 Acquaye AA, Payén SS, Vera E, Williams LA, Gilbert MR, Weathers SP, Armstrong TS. Identifying symptom recurrences in primary brain tumor patients using the MDASI-BT and qualitative interviews. Journal of Patient-Reported Outcomes. 3: 58. PMID 31444579 DOI: 10.1186/S41687-019-0143-0  0.555
2019 Milbury K, Li J, Weathers SP, Mallaiah S, Armstrong T, Li Y, Bruera E, Cohen L. Pilot randomized, controlled trial of a dyadic yoga program for glioma patients undergoing radiotherapy and their family caregivers. Neuro-Oncology Practice. 6: 311-320. PMID 31386042 DOI: 10.1093/Nop/Npy052  0.36
2019 Truitt G, Gittleman H, Leece R, Ostrom QT, Kruchko C, Armstrong TS, Gilbert MR, Barnholtz-Sloan JS. Partnership for defining the impact of 12 selected rare CNS tumors: a report from the CBTRUS and the NCI-CONNECT. Journal of Neuro-Oncology. PMID 31209773 DOI: 10.1007/S11060-019-03215-X  0.552
2019 Lee EQ, Chukwueke UN, Hervey-Jumper SL, de Groot JF, Leone JP, Armstrong TS, Chang SM, Arons D, Oliver K, Verble K, Musella A, Willmarth N, Alexander BM, Bates A, Doherty L, et al. Barriers to Accrual and Enrollment in Brain Tumor Trials. Neuro-Oncology. PMID 31175826 DOI: 10.1093/Neuonc/Noz104  0.428
2019 Waddle MR, Oudenhoven MD, Farin CV, Deal AM, Hoffman R, Yang H, Peterson J, Armstrong TS, Ewend MG, Wu J. Impacts of Surgery on Symptom Burden and Quality of Life in Pituitary Tumor Patients in the Subacute Post-operative Period. Frontiers in Oncology. 9: 299. PMID 31065545 DOI: 10.3389/Fonc.2019.00299  0.434
2019 Wu J, Yuan Y, Cordova C, Aboud O, Penas-Prado M, Theeler BJ, Bryla C, Su Y, Grajkowska E, McCoy A, Boris L, Siegel C, Antony R, Garren N, Lawhon T, ... Armstrong T, et al. Phase I trial of TG02 plus dose-dense or metronomic temozolomide for recurrent anaplastic astrocytoma and glioblastoma in adults. Journal of Clinical Oncology. 37: 2031-2031. DOI: 10.1200/Jco.2019.37.15_Suppl.2031  0.355
2019 Cordova C, Vera E, Aboud O, Antony R, Boris L, Bryla C, Burton E, Crandon S, Leggiero N, Reyes J, Siegel C, Theeler B, Vyas Y, Wall K, Wu J, ... ... Armstrong T, et al. RARE-35. MRI FINDINGS AT PROGRESSION IN ADULT PATIENTS WITH MEDULLOBLASTOMA Neuro-Oncology. 21: vi229-vi229. DOI: 10.1093/Neuonc/Noz175.958  0.424
2019 Siegel C, Raygada M, Acquaye A, Stearn S, Wall K, Crandon S, Stevens-Brown K, Wu J, Vera L, Theeler B, Reyes J, Leggiero N, Cordova C, Bryla C, Burton E, ... ... Armstrong T, et al. RARE-10. IMPROVING CARE FOR ADULT PATIENTS WITH RARE CNS TUMORS: THE NATIONAL CANCER INSTITUTE-COMPREHENSIVE ONCOLOGY NETWORK EVALUATING RARE CNS TUMORS (NCI-CONNECT) PROGRAM AND CLINIC Neuro-Oncology. 21: vi223-vi223. DOI: 10.1093/Neuonc/Noz175.933  0.58
2019 Ahluwalia M, Pugh S, Ellingson B, Kotecha R, Cloughesy T, Vogelbaum M, Aldape K, Cui Y, Armstrong T, Mehta M. RBTT-11. NRG ONCOLOGY NRG-BN006: A PHASE II/III RANDOMIZED, OPEN-LABEL STUDY OF TOCA 511 AND TOCA FC WITH STANDARD OF CARE COMPARED TO STANDARD OF CARE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA Neuro-Oncology. 21: vi220-vi221. DOI: 10.1093/Neuonc/Noz175.922  0.406
2019 King A, Leggiero N, Acquaye A, Vera E, Crandon S, Gilbert M, Armstrong T. RBTT-03. USE OF VIRTUAL REALITY ENVIRONMENTS TO IMPROVE SELF-REPORTED DISTRESS, MOOD DISTURBANCE AND OVERALL SYMPTOM BURDEN USING CORRELATIVE STRESS BIOMARKERS IN PRIMARY BRAIN TUMOR (PBT) PATIENTS Neuro-Oncology. 21: vi219-vi219. DOI: 10.1093/Neuonc/Noz175.915  0.733
2019 Randall J, Al Feghali K, Wefel J, Grosshans D, Dibaj S, Milton D, McAvoy S, Li J, McGovern S, McAleer M, Ghia A, Paulino A, Sulman E, Penas-Prado M, Wang J, ... ... Armstrong T, et al. RTHP-18. PROSPECTIVE PHASE II RANDOMIZED TRIAL COMPARING PROTON THERAPY VS. PHOTON IMRT FOR NEWLY DIAGNOSED GBM: SECONDARY ANALYSIS COMPARISON OF GENDER AND NEUTROPHIL-LYMPHOCYTE RATIO (NLR) IN GBM OUTCOMES Neuro-Oncology. 21: vi213-vi213. DOI: 10.1093/Neuonc/Noz175.889  0.443
2019 Young D, Dee Smart D, King A, Gilbert M, Armstrong T, Shuboni-Mulligan D. RDNA-13. DOSE RESPONSE CURVE FOR RADIATION-INDUCED HYPERSOMNOLENCE (RIH) IN A MOUSE MODEL OF CRANIAL RADIATION: BEHAVIORAL ANALYSIS OF SLEEP AND ACTIVITY Neuro-Oncology. 21: vi209-vi209. DOI: 10.1093/Neuonc/Noz175.872  0.784
2019 Shuboni-Mulligan D, Dahut M, Young D, Gilbert M, Armstrong T. RDNA-04. CIRCADIAN RHYTHMS AND RADIATION CHRONOTHERAPY IN GLIOBLASTOMA CELL LINES AND CENTRAL NERVOUS SYSTEM CELL CONTROLS Neuro-Oncology. 21: vi207-vi207. DOI: 10.1093/Neuonc/Noz175.864  0.743
2019 King A, Shuboni-Mulligan D, Vera E, Crandon S, Aboud O, Antony R, Boris L, Bryla C, Burton E, Cordova C, Gartland C, Grajkowska E, Penas-Prado M, Reyes J, Leggiero N, ... ... Armstrong T, et al. QOLP-36. THE IMPORTANCE OF SLEEP DISTURBANCE IN PRIMARY BRAIN TUMOR (PBT) PATIENTS: CLINICAL CHARACTERISTICS & CO-OCCURRENCE WITH TUMOR-RELATED & PSYCHOLOGICAL SYMPTOMS Neuro-Oncology. 21: vi205-vi206. DOI: 10.1093/Neuonc/Noz175.856  0.817
2019 Armstrong T, Puduvalli V, Walbert T, Peters K, Loughan A, Ahluwalia M, Province Warren P, Cachia D, Taylor J, O Blakeley J, Ganguli A, Khandelwal N, Kamalakar R, Noe L, Kumthekar P. QOLP-31. ASSESSING THE IMPACT OF GLIOBLASTOMA ON WORK PRODUCTIVITY IN PATIENTS AND THEIR CAREGIVERS Neuro-Oncology. 21: vi204-vi204. DOI: 10.1093/Neuonc/Noz175.851  0.353
2019 Yust-Katz S, Donthireddy V, Mandel J, Abunafeesa H, Patil N, Yadav D, Jabbour-Aida H, Wu J, Yuan Y, Tsavachidis S, Walbert T, Bondy M, Armstrong T. QOLP-30. CLINICAL PREDICTIVE MODEL FOR THE DEVELOPMENT OF VENOUS THROMBOEMBOLISM IN GLIOBLASTOMA Neuro-Oncology. 21: vi204-vi204. DOI: 10.1093/Neuonc/Noz175.850  0.323
2019 Leggiero N, Armstrong T, Vera E, Gilbert M, King A. QOLP-28. THE USE OF VIRTUAL REALITY FOR SYMPTOM MANAGEMENT: APPLICATION IN NEURO-ONCOLOGY Neuro-Oncology. 21: vi203-vi204. DOI: 10.1093/Neuonc/Noz175.848  0.759
2019 Armstrong T, Puduvalli V, Walbert T, Peters K, Loughan A, Ahluwalia M, Province Warren P, Cachia D, Taylor J, O Blakeley J, Ganguli A, Khandelwal N, Kamalakar R, Noe L, Kumthekar P. QOLP-20. IMPACT OF GLIOBLASTOMA ON PATIENT-REPORTED SYMPTOM BURDEN AND PHYSICAL ACTIVITY ASSESSED BY CONVENTIONAL INSTRUMENTS AND A NOVEL DEVICE–BASED TECHNOLOGY Neuro-Oncology. 21: vi201-vi202. DOI: 10.1093/Neuonc/Noz175.840  0.341
2019 Acquaye A, Wall K, Gilbert M, Armstrong T. QOLP-08. UNDERSTANDING THE EXPERIENCE OF YOUNG ADULTS (YAS) DIAGNOSED WITH AN EPENDYMOMA FROM THE ADULT EPENDYMOMA OUTCOMES PROJECT AND RARE CNS OUTCOMES AND RISK STUDY Neuro-Oncology. 21: vi199-vi199. DOI: 10.1093/Neuonc/Noz175.828  0.573
2019 Aboud O, Gilbert M, Armstrong T, Vera E, Wu J, Wall K, Theeler B, Siegel C, Reyes J, Leggiero N, Crandon S, Cordova C, Boris L, Bryla C, Burton E, et al. NIMG-32. CHALLENGES OF IMAGING INTERPRETATION TO PREDICT OLIGODENDROGLIOMA GRADE Neuro-Oncology. 21: vi168-vi168. DOI: 10.1093/Neuonc/Noz175.702  0.469
2019 Al Feghali K, Randall J, Wefel J, Guha-Thakurta N, Grosshans D, Dibaj S, McAvoy S, Li J, McGovern S, McAleer M, Ghia A, Paulino A, Sulman E, Penas-Prado M, Wang J, ... ... Armstrong T, et al. NIMG-03. PROSPECTIVE PHASE II RANDOMIZED TRIAL COMPARING PROTON THERAPY VS. PHOTON IMRT FOR GBM: SECONDARY ANALYSIS COMPARISON OF PROGRESSION FREE SURVIVAL BETWEEN RANO VS. CLINICAL AND RADIOLOGICAL ASSESSMENT Neuro-Oncology. 21: vi161-vi162. DOI: 10.1093/Neuonc/Noz175.675  0.518
2019 Briceno N, Abdullaev Z, Vera E, Blumental De Abreu F, Quezado M, Pack S, Xi L, Raffeld M, Gilbert M, Aldape K, Armstrong T. PATH-20. INVESTIGATION OF CLINICALLY AGGRESSIVE SPINAL CORD EPENDYMOMA THROUGH METHYLATION ANALYSIS Neuro-Oncology. 21: vi147-vi147. DOI: 10.1093/Neuonc/Noz175.616  0.489
2019 Lee E, Chukwueke U, Hervey-Jumper S, DeGroot J, Leone P, Armstrong T, Chang S, Arons D, Oliver K, Verble K, Musella A, Willmarth N, Alexander B, Bates A, Doherty L, et al. INNV-33. BARRIERS TO ACCRUAL AND ENROLLMENT IN BRAIN TUMOR TRIALS Neuro-Oncology. 21: vi137-vi137. DOI: 10.1093/Neuonc/Noz175.574  0.341
2019 Vera E, Gilbert M, Aboud O, Antony R, Boris L, Bryla C, Burton E, Cordova C, Crandon S, Leggiero N, Penas-Prado M, Reyes J, Siegel C, Theeler B, Wall K, ... ... Armstrong T, et al. HOUT-22. EVALUATING CLINICAL IMPACT UTILIZING THE RANO-PRO COLLABORATIVE’S STANDARDIZED PRIORITY CONSTRUCTS Neuro-Oncology. 21: vi116-vi117. DOI: 10.1093/Neuonc/Noz175.487  0.549
2019 Vyas Y, Vera E, Bryla C, Crandon S, Wu J, Wall K, Theeler B, Siegel C, Reyes J, Penas-Prado M, Leggiero N, Cordova C, Burton E, Antony R, Boris L, ... ... Armstrong T, et al. HOUT-04. ASSOCIATION OF COMMON PATIENT-REPORTED IMMUNOTHERAPY SYMPTOMATIC SIDE EFFECTS AND PSEUDOPROGRESSION IN PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS Neuro-Oncology. 21: vi112-vi112. DOI: 10.1093/Neuonc/Noz175.469  0.592
2019 Mendoza T, Rowe L, Vera E, Acquaye A, Gilbert M, Armstrong T. HOUT-01. ALOPECIA SYMPTOM IMPACT SCALE (ASIS): MEASURING THE SYMPTOMS OF ALOPECIA AND THEIR IMPACT IN PATIENTS WITH PRIMARY BRAIN TUMORS Neuro-Oncology. 21: vi111-vi112. DOI: 10.1093/Neuonc/Noz175.466  0.561
2019 Wu J, Bryla C, Su Y, Grajkowska E, McCoy A, Boris L, Antony R, Garren N, Siegel C, Cordova C, Aboud O, Vera E, Lawhon T, Penas-Prado M, Theeler B, ... ... Armstrong T, et al. ACTR-62. PHASE I TRIAL OF TG02 PLUS DOSE-DENSE OR METRONOMIC TEMOZOLOMIDE FOR RECURRENT HIGH-GRADE ASTROCYTOMA IN ADULTS Neuro-Oncology. 21: vi27-vi28. DOI: 10.1093/Neuonc/Noz175.104  0.453
2019 Armstrong T, Deshmukh S, Brown P, Gondi V, Benzinger T, Gilbert M, Tome W, Wefel J, Bruner D, Roberge D, Kundapur V, Devisetty K, Shah S, Usuki K, Baschnagel A, et al. ACTR-50. PRESERVATION OF NEUROCOGNITIVE FUNCTION & PATIENT-REPORTED SYMPTOMS WITH HIPPOCAMPAL AVOIDANCE (HA) DURING WHOLE-BRAIN RADIOTHERAPY (WBRT) FOR BRAIN METASTASES: LONG-TERM RESULTS OF NRG ONCOLOGY CC001 Neuro-Oncology. 21: vi24-vi25. DOI: 10.1093/Neuonc/Noz175.092  0.538
2019 Al Feghali K, Randall J, Wefel J, Guha-Thakurta N, Grosshans D, Dibej S, McAvoy S, Li J, McGovern S, McAleer M, Ghia A, Paulino A, Sulman E, Penas-Prado M, Wang J, ... ... Armstrong T, et al. Prospective Phase II Randomized Trial Comparing Proton Therapy vs. IMRT for Newly Diagnosed GBM: Secondary Analysis Comparison of Progression Free Survival between Clinical Radiological Assessment vs. Response Assessment in Neuro-Oncology (RANO) International Journal of Radiation Oncology*Biology*Physics. 105: S139. DOI: 10.1016/J.Ijrobp.2019.06.132  0.45
2018 Armstrong TS, Vera E, Zhou R, Acquaye AA, Sullaway CM, Berger AM, Breton G, Mahajan A, Wefel JS, Gilbert MR, Bondy M, Scheurer ME. Association of genetic variants with fatigue in patients with malignant glioma. Neuro-Oncology Practice. 5: 122-128. PMID 31386001 DOI: 10.1093/Nop/Npx020  0.51
2018 Vera E, Acquaye AA, Mendoza TR, Gilbert MR, Armstrong TS. Relationship between symptom burden and health status: analysis of the MDASI-BT and EQ-5D. Neuro-Oncology Practice. 5: 56-63. PMID 31385972 DOI: 10.1093/Nop/Npx010  0.425
2018 Cavalli FMG, Hübner JM, Sharma T, Luu B, Sill M, Zapotocky M, Mack SC, Witt H, Lin T, Shih DJH, Ho B, Santi M, Emery L, Hukin J, Dunham C, ... ... Armstrong TS, et al. Heterogeneity within the PF-EPN-B ependymoma subgroup. Acta Neuropathologica. PMID 30019219 DOI: 10.1007/S00401-018-1888-X  0.412
2018 Arvold ND, Armstrong TS, Warren KE, Chang SM, DeAngelis LM, Blakeley J, Chamberlain MC, Dunbar E, Loong HH, Macdonald DR, Reardon DA, Vogelbaum MA, Yuan Y, Weller M, van den Bent M, et al. Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group. Neuro-Oncology. PMID 29788429 DOI: 10.1093/Neuonc/Noy056  0.322
2018 Walker J, O'Brien B, Vera E, Armstrong T. Describing Symptom Burden and Functional Status at the Diagnosis of Leptomeningeal Metastasis. Oncology Nursing Forum. 45: 372-379. PMID 29683126 DOI: 10.1188/18.Onf.372-379  0.688
2018 Hall WA, Pugh SL, Wefel JS, Armstrong TS, Gilbert MR, Brachman DG, Werner-Wasik M, Wendland MM, Brown PD, Chao ST, Roof KS, Robins HI, Mehta MP, Curran WJ, Movsas B. Influence of Residual Disease Following Surgical Resection in Newly Diagnosed Glioblastoma on Clinical, Neurocognitive, and Patient Reported Outcomes. Neurosurgery. PMID 29618054 DOI: 10.1093/Neuros/Nyy003  0.522
2018 Aboud O, Raffeld M, Brown J, Sabersky A, Briceno N, Brown M, Chung H, Crandon S, Ji M, Levine J, Patel S, Reyes J, Siegel C, Vera E, Xi L, ... ... Armstrong T, et al. RARE-26. MUTATIONS IN MAPK PATHWAY GENES ARE CHARACTERISTIC AND CONFIRMATORY OF MULTINODULAR AND VACUOLATING NEURONAL TUMOR OF THE CEREBRUM Neuro-Oncology. 20: vi241-vi241. DOI: 10.1093/Neuonc/Noy148.999  0.361
2018 Armstrong T, Yuan Y, Wu J, Mendoza T, Vera E, Omuro A, Lieberman F, Robins H, Gerstner E, Wu J, Wen P, Mikkelsen T, Aldape K, Gilbert M. RARE-24. OBJECTIVE RESPONSE AND CLINICAL BENEFIT IN RECURRENT EPENDYMOMA IN ADULTS: FINAL REPORT OF CERN 08-02: A PHASE II STUDY OF DOSE-DENSE TEMOZOLOMIDE AND LAPATINIB Neuro-Oncology. 20: vi241-vi241. DOI: 10.1093/Neuonc/Noy148.998  0.359
2018 Boris L, Bryla C, Vera E, Aboud O, Garren N, Park D, Siegel C, Theeler B, Wu J, Armstrong T, Gilbert M. RARE-21. A DESCRIPTIVE REPORT OF PATIENTS WITH RARE CENTRAL NERVOUS SYSTEM (CNS) CANCERS ON AN NCI-CONNECT CANCER MOONSHOT IMMUNE CHECKPOINT INHIBITOR TRIAL Neuro-Oncology. 20: vi240-vi240. DOI: 10.1093/Neuonc/Noy148.995  0.373
2018 Figiel C, Shuboni-Mulligan D, Armstrong T, Smart D. RDNA-13. VALIDATION OF BEHAVIORAL ANALYSIS ACROSS AGE IN A MOUSE MODEL FOR FUTURE INVESTIGATION OF RADIATION-INDUCED HYPERSOMNOLENCE (RIH) IN PRIMARY BRAIN TUMOR (PBT) PATIENTS Neuro-Oncology. 20: vi224-vi224. DOI: 10.1093/Neuonc/Noy148.928  0.738
2018 Garren N, Vera E, Aboud O, Acquaye A, Boris L, Brown M, Crandon S, Ji M, Levine J, Reyes J, Romo C, Siegel C, Wu J, Gilbert M, Armstrong T. QOLP-26. PATIENT REPORTED OUTCOMES MEASUREMENT INFORMATION SYSTEM (PROMIS) SCREENING FOR ANXIETY & DEPRESSION IN CENTRAL NERVOUS SYSTEM(CNS) CANCER: LARGE COHORT REPORT FROM THE NEURO-ONCOLOGY BRANCH NATURAL HISTORY STUDY (NOB-NHS). Neuro-Oncology. 20: vi220-vi220. DOI: 10.1093/Neuonc/Noy148.912  0.379
2018 Acquaye A, Vera E, Aboud O, Armstrong T, Boris L, Brown M, Crandon S, Garren N, Ji M, Levine J, Romo C, Reyes J, Siegel C, Wu J, Mackey M, et al. QOLP-16. CAPTURING THE PRIMARY BRAIN TUMOR (PBT) PATIENT’S EXPERIENCE OF BODY IMAGE DISSATISFACTION: REPORT FROM THE NEURO-ONCOLOGY BRANCH-NATURAL HISTORY STUDY (NOB-NHS) Neuro-Oncology. 20: vi217-vi218. DOI: 10.1093/Neuonc/Noy148.902  0.427
2018 Acquaye A, Armstrong T, Vera E, Crandon S, Fletcher Ruiz M, Aboud O, Boris L, Brown M, Garren N, Ji M, Levine J, Romo C, Reyes J, Siegel C, Wu J, et al. QOLP-14. PRELIMINARY EXAMINATION OF CONFIRMED GLIOMA RISK FACTORS AMONG EPENDYMOMA PATIENTS IN THE NEURO-ONCOLOGY BRANCH NATURAL HISTORY STUDY (NOB-NHS) AND RISK AND OUTCOMES STUDY (ROS) Neuro-Oncology. 20: vi217-vi217. DOI: 10.1093/Neuonc/Noy148.900  0.356
2018 Mathen P, Armstrong T, Vera E, Acquaye A, Crandon S, Fletcher Ruiz M, Aboud O, Boris L, Brown M, Garren N, Ji M, Levine J, Mackey M, Romo C, Reyes J, et al. QOLP-09. ASSOCIATION BETWEEN BODY IMAGE INVESTMENT AND ALTERATION IN PATIENTS WITH PRIMARY BRAIN TUMORS Neuro-Oncology. 20: vi216-vi216. DOI: 10.1093/Neuonc/Noy148.895  0.457
2018 Rowe L, Vera E, Acquaye A, Crandon S, Fletcher Ruiz M, Aboud O, Boris L, Brown M, Garren N, Ji M, Levine J, Mackey M, Mathan P, Romo C, Reyes J, ... ... Armstrong T, et al. QOLP-06. BODY IMAGE DISTURBANCE IN PATIENTS WITH PRIMARY BRAIN TUMORS Neuro-Oncology. 20: vi215-vi215. DOI: 10.1093/Neuonc/Noy148.892  0.459
2018 Gondi V, Pugh S, D Brown P, Wefel J, Gilbert M, Bovi J, Robinson C, Tammie B, Tome W, Armstrong T, Bruner D, Khuntia D, Grosshans D, Konski A, Robidoux A, et al. NCOG-01. PRESERVATION OF NEUROCOGNITIVE FUNCTION (NCF) WITH HIPPOCAMPAL AVOIDANCE DURING WHOLE-BRAIN RADIOTHERAPY (WBRT) FOR BRAIN METASTASES: PRELIMINARY RESULTS OF PHASE III TRIAL NRG ONCOLOGY CC001 Neuro-Oncology. 20: vi172-vi172. DOI: 10.1093/Neuonc/Noy148.716  0.399
2018 Siegel C, Aboud O, Brown M, Chung H, Raffeld M, Crandon S, Ji M, Levine J, Vera E, Patel S, Reyes J, Armstrong T, Xi L, Acquaye A, Boris L, et al. PATH-52. UTILIZING NEXT GENERATION SEQUENCING REPORTS IN CLINICAL DECISION MAKING: REPORT FROM THE NATIONAL INSTITUTES OF HEALTH (NIH) NEURO-ONCOLOGY BRANCH (NOB) NATURAL HISTORY STUDY (NHS) PRIMARY BRAIN TUMOR PANEL (PBTP) Neuro-Oncology. 20: vi170-vi170. DOI: 10.1093/Neuonc/Noy148.706  0.422
2018 Briceno N, Crandon S, Vera E, Siegel C, Aboud O, Brown M, Chung H, Ji M, Levine J, Patel S, Reyes J, Raffeld M, Gilbert M, Xi L, Armstrong T. INNV-43. NUCLEIC ACID ADEQUACY FROM ARCHIVED FORMALIN-FIXED PARAFFIN EMBEDDED (FFPE) TUMOR TISSUE FOR NEXT-GENERATION SEQUENCING (NGS) IN NATIONAL CANCER INSTITUTE (NCI)- NATURAL HISTORY STUDY (NHS) OF PRIMARY CNS TUMOR Neuro-Oncology. 20: vi146-vi146. DOI: 10.1093/Neuonc/Noy148.611  0.415
2018 Li X, Vera E, Gilbert M, Celiku O, Armstrong T. INNV-41. MY STORI -- A SYMPTOM TRACKING AND REPORTING INSTRUMENT MOBILE APPLICATION FOR CENTRAL NERVOUS SYSTEM CANCER PATIENTS Neuro-Oncology. 20: vi146-vi146. DOI: 10.1093/Neuonc/Noy148.609  0.414
2018 Vera E, Levine J, Ji M, Grajkowska E, Crandon S, Gilbert M, Armstrong T. INNV-33. IMPLEMENTATION OF ELECTRONIC DATA CAPTURE FOR USE IN NATURAL HISTORY STUDIES: UTILITY OF CENTER FOR CANCER RESEARCHS (CCR) LABMATRIX AND SCRIBE SYSTEMS FOR THE NEURO-ONCOLOGY BRANCH NATURAL HISTORY STUDY (NOB-NHS) Neuro-Oncology. 20: vi145-vi145. DOI: 10.1093/Neuonc/Noy148.604  0.305
2018 Crandon S, Vera E, Acquaye A, Siegel C, Aboud O, Boris L, Brown M, Garren N, Ji M, Levine J, Romo C, Reyes J, Wu J, Gilbert M, Armstrong T. HOUT-12. CHARACTERIZATION OF SYMPTOM BURDEN IN MINORITY PATIENTS WITH CNS TUMORS: A REPORT FROM THE NEURO-ONCOLOGY BRANCH (NOB) NATURAL HISTORY STUDY (NHS) Neuro-Oncology. 20: vi115-vi115. DOI: 10.1093/Neuonc/Noy148.480  0.513
2018 Ruiz MF, Vera E, Acquaye A, Boris L, Brown M, Crandon S, Garren N, Ji M, Levine J, Reyes J, Siegel C, Wu J, Gilbert M, Armstrong T. HOUT-03. SCREENING FOR MOOD DISTURBANCE IN LONG-TERM CENTRAL NERVOUS SYSTEM (CNS) TUMOR SURVIVORS USING PATIENT REPORTED OUTCOMES MEASUREMENT INFORMATION SYSTEM (PROMIS): A NEURO-ONCOLOGY BRANCH NATURAL HISTORY STUDY (NOB-NHS) REPORT Neuro-Oncology. 20: vi113-vi113. DOI: 10.1093/Neuonc/Noy148.471  0.428
2018 Truitt G, Gittleman H, Ostrom Q, Kruchko C, Boscia A, Armstrong T, Gilbert M, Barnholtz-Sloan J. EXTH-61. PARTNERSHIP FOR DEFINING THE IMPACT OF 12 SELECT RARE CNS TUMORS: A REPORT FROM CBTRUS AND THE NCI-CONNECT Neuro-Oncology. 20: vi98-vi98. DOI: 10.1093/Neuonc/Noy148.408  0.433
2018 Puduvalli V, Wu J, Yuan Y, Armstrong T, Wu J, Giglio P, Xu J, Colman H, Walbert T, Raizer J, Groves M, Iwamoto F, Tran D, Avgeropoulos N, Paleologos N, et al. ACTR-13. A BAYESIAN ADAPTIVE RANDOMIZED PHASE II TRIAL OF BEVACIZUMAB VERSUS BEVACIZUMAB PLUS VORINOSTAT IN ADULTS WITH RECURRENT GLIOBLASTOMA FINAL RESULTS Neuro-Oncology. 20: vi13-vi13. DOI: 10.1093/Neuonc/Noy148.047  0.433
2017 Yust Katz S, Cachia D, Kamiya-Matsuoka C, Olar A, Theeler B, Penas Prado M, Gilbert MR, Armstrong T. Corrigendum to 'Ependymomas arising outside of the central nervous system: A case series and literature review' [J Clin Neurosci 47 (2018) 202-207]. Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia. PMID 29295763 DOI: 10.1016/J.Jocn.2017.12.011  0.395
2017 Aggarwal SS, Ott SD, Padhye NS, Meininger JC, Armstrong TS. Clinical and demographic predictors of concussion resolution in adolescents: A retrospective study. Applied Neuropsychology. Child. 1-11. PMID 29058480 DOI: 10.1080/21622965.2017.1381099  0.669
2017 Yust Katz S, Cachia D, Kamiya Matsuok C, Olar A, Theeler B, Penas Prado M, Gilbert MR, Armstrong T. Ependymomas arising outside of the central nervous system: A case series and literature review. Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia. PMID 29054328 DOI: 10.1016/J.Jocn.2017.10.026  0.453
2017 Aggarwal SS, Ott SD, Padhye NS, Meininger JC, Armstrong TS. Predictors Of Concussive Recovery In Adolescents Medicine & Science in Sports & Exercise. 49: 528. DOI: 10.1249/01.mss.0000518358.76009.18  0.64
2017 Walker J, O’Brien BJ, Armstrong TS, Gilbert MR, Casarez R, Wood G. QLIF-45. ASSOCIATIONS AMONG MEANING OF ILLNESS, SYMPTOM BURDEN, QUALITY OF LIFE AND DEPRESSION IN PATIENTS WITH LEPTOMENINGEAL METASTASIS Neuro-Oncology. 19: vi211-vi211. DOI: 10.1093/Neuonc/Nox168.852  0.391
2017 Vera E, Mendoza T, Crandon S, Lisa B, Garren N, Siegel C, Park DM, Sul J, Theeler B, Wu J, Gilbert MR, Armstrong T. QLIF-31. SYMPTOM BURDEN AND HEALTH STATUS OF PATIENTS WITH RARE VERSUS COMMON BRAIN TUMORS Neuro-Oncology. 19: vi208-vi208. DOI: 10.1093/Neuonc/Nox168.840  0.504
2017 Milbury K, Mallaiah S, Mahajan A, Armstrong TS, Weathers S, Li J, Cohen L. QLIF-21. FEASIBILITY RANDOMIZED CONTROLLED TRIAL OF A DYADIC YOGA PROGRAM FOR PATIENTS WITH BRAIN TUMORS UNDERGOING RADIOTHERAPY AND THEIR FAMILY CAREGIVERS Neuro-Oncology. 19: vi205-vi205. DOI: 10.1093/Neuonc/Nox168.831  0.375
2017 Acquaye AA, Garren N, Vera E, Lisa B, Siegel C, Park DM, Wu J, Crandon S, Theeler BJ, Sul J, Gilbert MR, Armstrong T. QLIF-17. ASSESSING DEPRESSION IN GLIOMA PATIENTS Neuro-Oncology. 19: vi204-vi205. DOI: 10.1093/Neuonc/Nox168.827  0.361
2017 Garren N, Acquaye AA, Vera E, Lisa B, Siegel C, Park DM, Sul J, Theeler BJ, Wu J, Crandon S, Gilbert M, Armstrong T. QLIF-13. EVALUATION OF ANXIETY SYMPTOMS AMONG BRAIN TUMOR PATIENTS; ARE WE PROVIDING APPROPRIATE, EFFECTIVE CARE? Neuro-Oncology. 19: vi203-vi204. DOI: 10.1093/Neuonc/Nox168.823  0.496
2017 Lisa B, Vera E, Wu J, Park DM, Bryla C, Crandon S, Garren N, McCoy A, Siegel C, Theeler BJ, Sul J, Gilbert M, Armstrong T. QLIF-03. UNUSUAL ADVERSE DRUG REACTIONS IN HIGH GRADE GLIOMA PATIENTS TREATED WITH TEMOZOLOMIDE Neuro-Oncology. 19: vi201-vi201. DOI: 10.1093/Neuonc/Nox168.814  0.358
2017 Siegel C, Armstrong T, Chung H, Crandon S, Patel S, Powers A, Quezado M, Ray-Chaudhury A, Vera E, Wu J, Xi L, Raffeld M, Gilbert M. PATH-40. STANDARDIZED MOLECULAR ANALYSIS OF PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS IN A RESEARCH BASED CLINICAL PRACTICE. AN INTRODUCTION TO THE PRIMARY CNS TUMOR NEXT GENERATION SEQUENCING (NGS) PANEL Neuro-Oncology. 19: vi179-vi180. DOI: 10.1093/Neuonc/Nox168.730  0.501
2017 Chung C, Brown PD, McAvoy S, Grosshans DR, Dibaj S, Guha-Thakurta N, Li J, McGovern SL, Mcaleer MF, Ghia A, Paulino A, Sulman E, Penas-Prado M, Wang J, de Groot J, ... ... Armstrong TS, et al. ACTR-72. A PROSPECTIVE PHASE II RANDOMIZED TRIAL TO COMPARE INTENSITY MODULATED PROTON RADIOTHERAPY (IMPT) VS. INTENSITY MODULATED RADIOTHERAPY (IMRT) FOR NEWLY DIAGNOSED GLIOBLASTOMA (GBM) Neuro-Oncology. 19: vi16-vi16. DOI: 10.1093/Neuonc/Nox168.059  0.335
2017 Wu J, Bryla C, McCoy A, Lisa B, Garren N, Siegel C, Grajkowska E, Theeler B, Park DM, Parrott T, Armstrong TS, Yuan Y, Gilbert MR. ACTR-69. PHASE I TRIAL OF TG02 PLUS DOSE-DENSE OR METRONOMIC TEMOZOLOMIDE FOR ADULTS WITH RECURRENT ANAPLASTIC ASTROCYTOMA AND GLIOBLASTOMA Neuro-Oncology. 19: vi15-vi15. DOI: 10.1093/Neuonc/Nox168.056  0.433
2017 Armstrong TS, Gilbert MR, Bondy M, Sulman E, Yuan Y, Zhou R, Vera E, Wendland M, Pugh S, Scheurer M. OS05.6 Final risk model for Temozolomide (TMZ)-Myelotoxicity in patients with Glioblastoma treated on NRG Oncology’s RTOG 0825 Neuro-Oncology. 19: iii10-iii10. DOI: 10.1093/Neuonc/Nox036.033  0.454
2016 Sulman EP, Ismaila N, Armstrong TS, Tsien C, Batchelor TT, Cloughesy T, Galanis E, Gilbert M, Gondi V, Lovely M, Mehta M, Mumber MP, Sloan A, Chang SM. Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016707562. PMID 27893327 DOI: 10.1200/Jco.2016.70.7562  0.408
2016 Acquaye AA, Vera E, Gilbert MR, Armstrong TS. Clinical presentation and outcomes for adult ependymoma patients. Cancer. PMID 27679985 DOI: 10.1002/Cncr.30355  0.457
2016 Armstrong TS, Shade MY, Breton G, Gilbert MR, Mahajan A, Scheurer ME, Vera E, Berger AM. Sleep-wake disturbance in patients with brain tumors. Neuro-Oncology. PMID 27286798 DOI: 10.1093/Neuonc/Now119  0.44
2016 Ramaswamy V, Hielscher T, Mack SC, Lassaletta A, Lin T, Pajtler KW, Jones DT, Luu B, Cavalli FM, Aldape K, Remke M, Mynarek M, Rutkowski S, Gururangan S, McLendon RE, ... ... Armstrong TS, et al. Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27269943 DOI: 10.1200/Jco.2015.65.7825  0.311
2016 Wu J, Armstrong TS, Gilbert MR. Biology and management of ependymomas. Neuro-Oncology. PMID 27022130 DOI: 10.1093/Neuonc/Now016  0.476
2016 Helfer JL, Wen PY, Blakeley J, Gilbert MR, Armstrong TS. Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials clinical outcome assessment endpoints workshop (October 15, 2014, Bethesda MD). Neuro-Oncology. 18: ii26-ii36. PMID 26989130 DOI: 10.1093/Neuonc/Nov270  0.475
2016 Armstrong TS, Bishof AM, Brown PD, Klein M, Taphoorn MJ, Theodore-Oklota C. Determining priority signs and symptoms for use as clinical outcomes assessments in trials including patients with malignant gliomas: Panel 1 Report. Neuro-Oncology. 18: ii1-ii12. PMID 26989127 DOI: 10.1093/neuonc/nov267  0.373
2016 Zhou R, Scheurer ME, Gilbert MR, Bondy M, Sulman EP, Yuan Y, Liu Y, Vera E, Wendland MM, Brachman D, Bearden J, McGovern SL, Wilson SS, Judy KD, Robins HI, ... ... Armstrong TS, et al. Polymorphisms risk modeling for vascular toxicity in patients with glioblastoma treated on NRG Oncology/RTOG 0825. Journal of Clinical Oncology. 34: 2049-2049. DOI: 10.1200/Jco.2016.34.15_Suppl.2049  0.362
2016 Vera E, Scheurer ME, Zhou R, Acquaye AA, Sullaway CM, Berger AM, Breton G, Mahajan A, Wefel JS, Gilbert MR, Armstrong TS. Investigation of risk factors associated with fatigue in glioma patients. Journal of Clinical Oncology. 34: 2018-2018. DOI: 10.1200/Jco.2016.34.15_Suppl.2018  0.456
2016 Yust-Katz S, Cachia D, Kamiya-Matsuoka C, Theeler BJ, Olar A, Prado MP, Armstrong T, Gilbert M. RARE-03. EPENDYMOMAS ARISING OUTSIDE OF THE CENTRAL NERVOUS SYSTEM: A CASE SERIES Neuro-Oncology. 18: vi162-vi162. DOI: 10.1093/Neuonc/Now212.672  0.301
2016 Acquaye AA, Vera E, Gilbert MR, Armstrong TS. QLIF-17. THE IMPORTANCE OF THE CERN FOUNDATION ADULT EPENDYMOMA OUTCOMES PROJECT Neuro-Oncology. 18: vi159-vi159. DOI: 10.1093/Neuonc/Now212.662  0.304
2016 Hwang E, Hardy K, Armstrong T, Acquaye A, Gioia A, Gilbert M, Mendoza T. QOS-12THE ASSOCIATION OF SOCIODEMOGRAPHIC AND MEDICAL FACTORS WITH CLINICAL OUTCOMES ASSESSMENTS (COAS) IN CHILDREN WITH EPENDYMOMA: RESULTS OF THE PEDIATRIC EPENDYMOMA OUTCOMES (PEO) PROJECT Neuro-Oncology. 18: iii147.4-iii147. DOI: 10.1093/Neuonc/Now081.12  0.364
2015 Armstrong TS, Grant R, Gilbert MR, Lee JW, Norden AD. Epilepsy in glioma patients: mechanisms, management, and impact of anticonvulsant therapy. Neuro-Oncology. PMID 26527735 DOI: 10.1093/Neuonc/Nov269  0.4
2015 Cachia D, Kamiya-Matsuoka C, Mandel JJ, Olar A, Cykowski MD, Armstrong TS, Fuller GN, Gilbert MR, De Groot JF. Primary and secondary gliosarcomas: clinical, molecular and survival characteristics. Journal of Neuro-Oncology. PMID 26354773 DOI: 10.1007/S11060-015-1930-Y  0.453
2015 Ladha H, Pawar T, Gilbert MR, Mandel J, O-Brien B, Conrad C, Fields M, Hanna T, Loch C, Armstrong TS. Wound healing complications in brain tumor patients on Bevacizumab. Journal of Neuro-Oncology. PMID 26298437 DOI: 10.1007/S11060-015-1868-0  0.337
2015 Armstrong TS, Vera-Bolanos E, Acquaye AA, Gilbert MR, Ladha H, Mendoza T. The symptom burden of primary brain tumors: evidence for a core set of tumor and treatment-related symptoms. Neuro-Oncology. PMID 26289592 DOI: 10.1093/Neuonc/Nov166  0.532
2015 Acquaye AA, Lin L, Vera-Bolanos E, Gilbert MR, Armstrong TS. Hope and mood changes throughout the primary brain tumor illness trajectory. Neuro-Oncology. PMID 26109686 DOI: 10.1093/Neuonc/Nov101  0.495
2015 Yust-Katz S, Mandel JJ, Wu J, Yuan Y, Webre C, Pawar TA, Lhadha HS, Gilbert MR, Armstrong TS. Venous thromboembolism (VTE) and glioblastoma. Journal of Neuro-Oncology. 124: 87-94. PMID 25985958 DOI: 10.1200/Jco.2014.32.15_Suppl.2033  0.445
2015 Pajtler KW, Witt H, Sill M, Jones DT, Hovestadt V, Kratochwil F, Wani K, Tatevossian R, Punchihewa C, Johann P, Reimand J, Warnatz HJ, Ryzhova M, Mack S, Ramaswamy V, ... ... Armstrong TS, et al. Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. Cancer Cell. 27: 728-43. PMID 25965575 DOI: 10.1016/J.Ccell.2015.04.002  0.433
2015 Liu Y, Zhou R, Sulman EP, Scheurer ME, Boehling N, Armstrong GN, Tsavachidis S, Liang FW, Etzel CJ, Conrad CA, Gilbert MR, Armstrong TS, Bondy ML, Wefel JS. Genetic Modulation of Neurocognitive Function in Glioma Patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 3340-6. PMID 25904748 DOI: 10.1158/1078-0432.Ccr-15-0168  0.407
2015 Armstrong TS, Ying Y, Wu J, Acquaye AA, Vera-Bolanos E, Gilbert MR, Brown PD, Vardy J, Chung C. The relationship between corticosteroids and symptoms in patients with primary brain tumors: utility of the Dexamethasone Symptom Questionnaire-Chronic. Neuro-Oncology. 17: 1114-20. PMID 25862766 DOI: 10.1093/Neuonc/Nov054  0.499
2015 Lin L, Chien LC, Acquaye AA, Vera-Bolanos E, Gilbert MR, Armstrong TS. Significant predictors of patients' uncertainty in primary brain tumors. Journal of Neuro-Oncology. 122: 507-15. PMID 25805495 DOI: 10.1007/S11060-015-1756-7  0.499
2015 Olar A, Wani KM, Alfaro-Munoz KD, Heathcock LE, van Thuijl HF, Gilbert MR, Armstrong TS, Sulman EP, Cahill DP, Vera-Bolanos E, Yuan Y, Reijneveld JC, Ylstra B, Wesseling P, Aldape KD. IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas. Acta Neuropathologica. 129: 585-96. PMID 25701198 DOI: 10.1007/S00401-015-1398-Z  0.409
2015 Cachia D, Wani K, Penas-Prado M, Olar A, McCutcheon IE, Benjamin RS, Armstrong TS, Gilbert MR, Aldape KD. C11orf95-RELA fusion present in a primary supratentorial ependymoma and recurrent sarcoma. Brain Tumor Pathology. 32: 105-11. PMID 25388523 DOI: 10.1007/S10014-014-0205-1  0.406
2015 Walbert T, Mendoza TR, Vera-Bolaños E, Acquaye A, Gilbert MR, Armstrong TS. Symptoms and socio-economic impact of ependymoma on adult patients: results of the Adult Ependymoma Outcomes Project 2. Journal of Neuro-Oncology. 121: 341-8. PMID 25359395 DOI: 10.1007/S11060-014-1638-4  0.486
2015 Vera-Bolanos E, Aldape K, Yuan Y, Wu J, Wani K, Necesito-Reyes MJ, Colman H, Dhall G, Lieberman FS, Metellus P, Mikkelsen T, Omuro A, Partap S, Prados M, Robins HI, ... ... Armstrong TS, et al. Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients. Neuro-Oncology. 17: 440-7. PMID 25121770 DOI: 10.1093/Neuonc/Nou162  0.462
2015 Puduvalli VK, Wu J, Yuan Y, Armstrong TS, Groves MD, Raizer JJ, Giglio P, Colman H, Peereboom DM, Walbert T, Avgeropoulos NG, Iwamoto FM, Chamberlain MC, Paleologos N, Fink KL, et al. Brain Tumor Trials Collaborative Bayesian Adaptive Randomized Phase II trial of bevacizumab plus vorinostat versus bevacizumab alone in adults with recurrent glioblastoma (BTTC-1102). Journal of Clinical Oncology. 33: 2012-2012. DOI: 10.1200/Jco.2015.33.15_Suppl.2012  0.422
2015 Bolanos EV, Acquaye A, Mendoza T, Gilbert M, Armstrong TS. QOL-25EVALUATION OF THE UTILITY OF THE EQ-5D AND MDASI-BT IN PRIMARY BRAIN TUMOR PATIENTS Neuro-Oncology. 17: v193.3-v193. DOI: 10.1093/Neuonc/Nov230.25  0.488
2015 Hwang E, Hardy K, Armstrong T, Acquaye A, Gilbert M, Mendoza T. QOL-12SELF- AND PROXY-REPORTED CLINICAL OUTCOMES ASSESSMENTS (COAS) IN A LARGE COHORT OF CHILDREN WITH EPENDYMOMA. Neuro-Oncology. 17: v190.3-v190. DOI: 10.1093/Neuonc/Nov230.12  0.355
2015 Leisy A, Armstrong T, Cron S. PCSM-07SYMPTOM BURDEN OF PATIENTS IN FOLLOW-UP FOR PRIMARY BRAIN TUMOR Neuro-Oncology. 17: v177.2-v177. DOI: 10.1093/neuonc/nov227.07  0.376
2015 Leisy A, Armstrong T, Acquaye A, Vera-Bolanos E, Gilbert M, Cron S. PCSM-06COMPARISON OF THE SYMPTOM BURDEN IN ACTIVE TREATMENT VERSUS FOLLOW-UP FOR PRIMARY BRAIN TUMOR PATIENTS Neuro-Oncology. 17: v177.1-v177. DOI: 10.1093/Neuonc/Nov227.06  0.464
2015 Wefel J, Bradshaw M, Sullaway C, Gilbert M, Armstrong T. NCO-17A BRAIN-PLASTICITY BASED COMPUTERIZED INTERVENTION TO TREAT ATTENTION AND MEMORY PROBLEMS IN ADULT BRAIN TUMOR (BT) SURVIVORS Neuro-Oncology. 17: v149.4-v150. DOI: 10.1093/Neuonc/Nov223.17  0.402
2015 Zhou R, Scheurer M, Gilbert M, Bondy M, Sulman E, Yuan Y, Liu Y, Vera-Bolanos E, Wendland M, Brachman D, Bearden J, McGovern S, Wilson S, Judy K, Robins HI, ... ... Armstrong T, et al. EPID-33RISK MODELING FOR VASCULAR TOXICITY IN PATIENTS WITH GLIOBLASTOMA (GBM) TREATED ON NRG ONCOLOGY/RTOG 0825 Neuro-Oncology. 17: v85.3-v85. DOI: 10.1093/Neuonc/Nov213.33  0.383
2015 Scheurer ME, Zhou R, Gilbert MR, Bondy ML, Sulman EP, Yuan Y, Liu Y, Vera-Bolanos E, Wendland MM, Brachman DG, Stieber VW, Komaki RR, Flickinger JC, Kenyon LC, Robins HI, ... ... Armstrong T, et al. EPID-25GERMLINE POLYMORPHISMS IN MGMT INCREASE ABILITY TO MODEL TEMOZOLOMIDE (TMZ)-RELATED MYELOTOXICITY RISK IN PATIENTS WITH GLIOBLASTOMA (GBM) TREATED ON NRG ONCOLOGY/RTOG 0825 Neuro-Oncology. 17: v83.3-v83. DOI: 10.1093/Neuonc/Nov213.25  0.369
2015 Wu J, Puduvalli VK, Yuan Y, Armstrong T, Walker B, Upshaw C, Giglio P, Colman H, Groves MD, Raizer J, Walbert T, Tran D, Avgeropoulos N, Iwamoto F, Peereboom D, et al. ATCT-34BAYESIAN ADAPTIVE RANDOMIZED PHASE II TRIAL OF BEVACIZUMAB PLUS VORINOSTAT VERSUS BEVACIZUMAB ALONE IN ADULTS WITH RECURRENT GLIOBLASTOMA Neuro-Oncology. 17: v9.2-v9. DOI: 10.1093/Neuonc/Nov206.34  0.48
2015 Hall W, Pugh S, Gilbert M, Wefel J, Armstrong T, Wendland M, Brachman D, Roof K, Brown P, Crocker I, Robins H, Lee R, Chao S, Kim L, Srkalovic G, et al. Bevacizumab Use in Patients With Subtotal Resection of Newly Diagnosed Glioblastoma (GBM): A Secondary Analysis of NRG Oncology/RTOG 0825 International Journal of Radiation Oncology*Biology*Physics. 93: S110. DOI: 10.1016/J.Ijrobp.2015.07.2257  0.412
2014 Kamiya-Matsuoka C, Cachia D, Olar A, Armstrong TS, Gilbert MR. Primary brain tumors and posterior reversible encephalopathy syndrome. Neuro-Oncology Practice. 1: 184-190. PMID 26034631 DOI: 10.1093/Nop/Npu024  0.488
2014 Cahill JE, Lin L, LoBiondo-Wood G, Armstrong TS, Acquaye AA, Vera-Bolanos E, Gilbert MR, Padhye NS. Personal health records, symptoms, uncertainty, and mood in brain tumor patients. Neuro-Oncology Practice. 1: 64-70. PMID 26034618 DOI: 10.1093/Nop/Npu005  0.791
2014 Armstrong TS, Vera-Bolanos E, Acquaye A, Gilbert MR, Mendoza TR. Impact of recall period on primary brain tumor patient's self-report of symptoms. Neuro-Oncology Practice. 1: 55-63. PMID 26034617 DOI: 10.1093/Nop/Npu006  0.504
2014 Gilbert MR, Armstrong TS, Pope WB, van den Bent MJ, Wen PY. Facing the future of brain tumor clinical research. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 5591-600. PMID 25398842 DOI: 10.1158/1078-0432.Ccr-14-0835  0.468
2014 Armstrong TS, Gilbert MR. Patient reported endpoints for measuring clinical benefit in (high grade glioma) primary brain tumor patients. Current Treatment Options in Oncology. 15: 519-28. PMID 25173554 DOI: 10.1007/S11864-014-0302-8  0.555
2014 Gilbert MR, Dignam J, Pugh S, Armstrong TS, Wefel JS, Aldape K, Stupp R, Hegi M, Won M, Curran WJ, Mehta MP. Reply to M.C. Chamberlain. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 1634-5. PMID 24752060 DOI: 10.1200/Jco.2013.54.9717  0.444
2014 Yust-Katz S, de Groot JF, Liu D, Wu J, Yuan Y, Anderson MD, Conrad CA, Milbourne A, Gilbert MR, Armstrong TS. Pregnancy and glial brain tumors. Neuro-Oncology. 16: 1289-94. PMID 24615863 DOI: 10.1093/Neuonc/Nou019  0.425
2014 Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. The New England Journal of Medicine. 370: 699-708. PMID 24552317 DOI: 10.1056/Nejmoa1308573  0.414
2014 Cahill JE, Gilbert MR, Armstrong TS. Personal health records as portal to the electronic medical record. Journal of Neuro-Oncology. 117: 1-6. PMID 24477621 DOI: 10.1007/S11060-013-1333-X  0.773
2014 Yust-Katz S, Mandel J, Ying Y, Wu J, Courtney C, Ladha H, Pawar T, Gilbert M, Armstrong T. SP-05 * VENOUS THROMBOEMBOLISM AND GLIOBLASTOMA Neuro-Oncology. 16: v212-v212. DOI: 10.1093/Neuonc/Nou276.5  0.444
2014 Liu Y, Zhou R, Sulman E, Scheurer M, Boehling N, Gilbert M, Armstrong T, Bondy M, Wefel J. ED-17 * GENETIC MODULATION OF NEUROCOGNITIVE FUNCTION AND OUTCOMES IN GLIOMA PATIENTS Neuro-Oncology. 16: v69-v69. DOI: 10.1093/Neuonc/Nou253.17  0.337
2014 Kamiya-Matsuoka C, Cachia D, Armstrong T, Gilbert M. CN-09 * POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME AND PRIMARY BRAIN TUMORS Neuro-Oncology. 16: v47-v48. DOI: 10.1093/Neuonc/Nou243.9  0.501
2014 Zhou R, Scheurer M, Vera-Bolanos E, Gilbert M, Bondy M, Sulman E, Hilsenbeck S, Wendland M, Brachman D, Roof K, Komaki R, Deutsch M, Andrews D, Anderson B, Lee RJ, ... ... Armstrong T, et al. CN-21 * RISK MODELING FOR TEMOZOLOMIDE (TMZ)-MYELOTOXICITY IN PATIENTS WITH GLIOBLASTOMA TREATED ON RTOG 0825 Neuro-Oncology. 16: v50-v50. DOI: 10.1093/Neuonc/Nou243.21  0.363
2014 Pawar T, Ladha H, Mandel J, Gilbert M, O'Brien B, Hamza M, Armstrong T. CN-15 * ADVERSE EFFECTS OF BEVACIZUMAB IN BRAIN TUMOR PATIENTS Neuro-Oncology. 16: v49-v49. DOI: 10.1093/Neuonc/Nou243.15  0.43
2014 Wani K, Armstrong TS, Jones DT, Vera-Bolanos E, Witt H, Capper D, Pfister SM, Gilbertson RJ, Gilbert MR, Aldape K. BI-30 * CHARACTERIZATION OF L1CAM AS A CLINICAL MARKER FOR THE C11orf95-RELA FUSION IN SUPRATENTORIAL EPENDYMOMAS Neuro-Oncology. 16: v30-v30. DOI: 10.1093/Neuonc/Nou239.30  0.372
2014 Ladha H, Pawar T, Gilbert M, O'Brien B, Conrad C, Fields M, Hanna T, Loch C, Armstrong T. AI-18 * WOUND HEALING COMPLICATIONS IN A SERIES OF BRAIN TUMOR PATIENTS ON BEVACIZUMAB Neuro-Oncology. 16: v5-v5. DOI: 10.1093/Neuonc/Nou238.18  0.349
2014 Gilbert M, Yuan Y, Wani K, Wu J, Omuro A, Lieberman F, Robins HI, Gerstner E, Wu J, Wen P, Mikkelsen T, Armstrong T, Aldape K. AT-23 * A PHASE II STUDY OF LAPATINIB AND DOSE-DENSE TEMOZOLOMIDE (TMZ) FOR ADULTS WITH RECURRENT EPENDYMOMA: A CERN CLINICAL TRIAL Neuro-Oncology. 16: v13-v13. DOI: 10.1093/Neuonc/Nou237.23  0.473
2013 Armstrong TS, Wefel JS, Wang M, Gilbert MR, Won M, Bottomley A, Mendoza TR, Coens C, Werner-Wasik M, Brachman DG, Choucair AK, Mehta M. Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 4076-84. PMID 24101048 DOI: 10.1200/Jco.2013.49.6067  0.533
2013 Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi ME, Jaeckle KA, Armstrong TS, Wefel JS, Won M, Blumenthal DT, Mahajan A, Schultz CJ, Erridge S, Baumert B, Hopkins KI, et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 4085-91. PMID 24101040 DOI: 10.1200/Jco.2013.49.6968  0.433
2013 Ghia AJ, Mahajan A, Allen PK, Armstrong TS, Lang FF, Gilbert MR, Brown PD. Supratentorial gross-totally resected non-anaplastic ependymoma: population based patterns of care and outcomes analysis. Journal of Neuro-Oncology. 115: 513-20. PMID 24085643 DOI: 10.1007/S11060-013-1254-8  0.414
2013 Acquaye AA, Vera-Bolanos E, Armstrong TS, Gilbert MR, Lin L. Mood disturbance in glioma patients. Journal of Neuro-Oncology. 113: 505-12. PMID 23677748 DOI: 10.1007/s11060-013-1143-1  0.482
2013 Lin L, Chiang HH, Acquaye AA, Vera-Bolanos E, Gilbert MR, Armstrong TS. Uncertainty, mood states, and symptom distress in patients with primary brain tumors: analysis of a conceptual model using structural equation modeling. Cancer. 119: 2796-806. PMID 23661311 DOI: 10.1002/cncr.28121  0.512
2013 Raghunathan A, Wani K, Armstrong TS, Vera-Bolanos E, Fouladi M, Gilbertson R, Gajjar A, Goldman S, Lehman NL, Metellus P, Mikkelsen T, Necesito-Reyes MJ, Omuro A, Packer RJ, Partap S, et al. Histological predictors of outcome in ependymoma are dependent on anatomic site within the central nervous system. Brain Pathology (Zurich, Switzerland). 23: 584-94. PMID 23452038 DOI: 10.1111/Bpa.12050  0.41
2013 Armstrong TS. Measuring clinical benefit: use of patient-reported outcomes (PRO) in primary brain tumor clinical trials. Current Oncology Reports. 15: 27-32. PMID 23054936 DOI: 10.1007/s11912-012-0276-2  0.379
2013 Wefel JS, Pugh SL, Armstrong TS, Gilbert MR, Won M, Wendland MM, Brachman D, Komaki R, Crocker IR, Robins HI, Lee RJ, Mehta MP. Neurocognitive function (NCF) outcomes in patients with glioblastoma (GBM) enrolled in RTOG 0825. Journal of Clinical Oncology. 31: 2004-2004. DOI: 10.1200/Jco.2013.31.15_Suppl.2004  0.367
2013 Armstrong TS, Won M, Wefel JS, Gilbert MR, Pugh SL, Brachman D, Komaki R, Crocker IR, Robins HI, Lee RJ, Mehta MP, Wendland MM. Comparative impact of treatment on patient reported outcomes (PROs) in patients with glioblastoma (GBM) enrolled in RTOG 0825. Journal of Clinical Oncology. 31: 2003-2003. DOI: 10.1200/Jco.2013.31.15_Suppl.2003  0.477
2012 Armstrong TS, Gilbert MR. Practical strategies for management of fatigue and sleep disorders in people with brain tumors. Neuro-Oncology. 14: iv65-72. PMID 23095832 DOI: 10.1093/Neuonc/Nos210  0.453
2012 Lin L, Acquaye AA, Vera-Bolanos E, Cahill JE, Gilbert MR, Armstrong TS. Validation of the Mishel's uncertainty in illness scale-brain tumor form (MUIS-BT). Journal of Neuro-Oncology. 110: 293-300. PMID 22965831 DOI: 10.1007/S11060-012-0971-8  0.803
2012 Amirian ES, Armstrong TS, Aldape KD, Gilbert MR, Scheurer ME. Predictors of survival among pediatric and adult ependymoma cases: a study using Surveillance, Epidemiology, and End Results data from 1973 to 2007. Neuroepidemiology. 39: 116-24. PMID 22846789 DOI: 10.1159/000339320  0.439
2012 Cahill J, LoBiondo-Wood G, Bergstrom N, Armstrong T. Brain tumor symptoms as antecedents to uncertainty: an integrative review. Journal of Nursing Scholarship : An Official Publication of Sigma Theta Tau International Honor Society of Nursing / Sigma Theta Tau. 44: 145-55. PMID 22564342 DOI: 10.1111/j.1547-5069.2012.01445.x  0.788
2012 Galanis E, Wu W, Cloughesy T, Lamborn K, Mann B, Wen PY, Reardon DA, Wick W, Macdonald D, Armstrong TS, Weller M, Vogelbaum M, Colman H, Sargent DJ, van den Bent MJ, et al. Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. The Lancet. Oncology. 13: e196-204. PMID 22554547 DOI: 10.1016/S1470-2045(11)70406-5  0.362
2012 Armstrong TS, Wefel JS, Gning I, Acquaye A, Vera-Bolanos E, Gilbert MR, Cleeland CS, Mendoza T. Congruence of primary brain tumor patient and caregiver symptom report. Cancer. 118: 5026-37. PMID 22415423 DOI: 10.1002/Cncr.27483  0.511
2012 Wani K, Armstrong TS, Vera-Bolanos E, Raghunathan A, Ellison D, Gilbertson R, Vaillant B, Goldman S, Packer RJ, Fouladi M, Pollack I, Mikkelsen T, Prados M, Omuro A, Soffietti R, et al. A prognostic gene expression signature in infratentorial ependymoma. Acta Neuropathologica. 123: 727-38. PMID 22322993 DOI: 10.1007/S00401-012-0941-4  0.421
2012 Armstrong TS, Wen PY, Gilbert MR, Schiff D. Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors. Neuro-Oncology. 14: 1203-14. PMID 22307472 DOI: 10.1093/Neuonc/Nor223  0.414
2012 Penas-Prado M, Armstrong TS, Gilbert MR. Glioblastoma. Handbook of Clinical Neurology. 105: 485-506. PMID 22230514 DOI: 10.1016/B978-0-444-53502-3.00004-5  0.392
2012 Amirian ES, Armstrong TS, Gilbert MR, Scheurer ME. Predictors of survival among older adults with ependymoma. Journal of Neuro-Oncology. 107: 183-9. PMID 21952907 DOI: 10.1007/S11060-011-0730-2  0.462
2012 Habets EJ, Taphoorn MJ, Nederend S, Klein M, Delgadillo D, Hoang-Xuan K, Bottomley A, Allgeier A, Seute T, Gijtenbeek AM, De Gans J, Enting RH, Tijssen CC, Van den Bent MJ, Reijneveld JC, ... ... Armstrong TS, ... ... Armstrong TS, ... ... Armstrong TS, ... ... Armstrong TS, ... ... Armstrong TS, ... ... Armstrong TS, et al. CLIN-SYMPTOM MANAGEMENT/QUALITY OF LIFE Neuro-Oncology. 14: vi153-vi159. DOI: 10.1093/Neuonc/Nos240  0.638
2011 Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi M, Jaeckle KA, Armstrong TS, Wefel JS, Won M, Blumenthal DT, Mahajan A, Schultz CJ, Erridge SC, Brown PD, Chakravarti A, et al. RTOG 0525: A randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2006. PMID 28023891 DOI: 10.1200/Jco.2011.29.15_Suppl.2006  0.344
2011 Armstrong TS, Wefel JS, Wang M, Won M, Bottomley A, Mendoza TR, Coens C, Werner-Wasik M, Brachman D, Choucair AK, Gilbert MR. Clinical utility of neurocognitive function (NCF), quality of life (QOL), and symptom assessment as prognostic factors for survival and measures of treatment effects on RTOG 0525. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2016. PMID 28023866 DOI: 10.1200/Jco.2011.29.15_Suppl.2016  0.383
2011 Shonka NA, Armstrong TS, Prabhu SS, Childress A, Choi S, Langford LA, Gilbert MR. Atypical teratoid/rhabdoid tumors in adults: a case report and treatment-focused review. Journal of Clinical Medicine Research. 3: 85-92. PMID 21811535 DOI: 10.4021/Jocmr535W  0.449
2011 Armstrong TS, Vera-Bolanos E, Gilbert MR. Clinical course of adult patients with ependymoma: results of the Adult Ependymoma Outcomes Project. Cancer. 117: 5133-41. PMID 21538344 DOI: 10.1002/Cncr.26181  0.526
2011 Cahill JE, Armstrong TS. Caring for an adult with a malignant primary brain tumor. Nursing. 41: 28-33; quiz 33-4. PMID 21537213 DOI: 10.1097/01.NURSE.0000397930.50420.c6  0.755
2011 Armstrong TS, Vera-Bolanos E, Gning I, Acquaye A, Gilbert MR, Cleeland C, Mendoza T. The impact of symptom interference using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT) on prediction of recurrence in primary brain tumor patients. Cancer. 117: 3222-8. PMID 21264841 DOI: 10.1002/Cncr.25892  0.529
2011 Armstrong TS, Gilbert MR. Patient profiling for treatment toxicity: potential use of clinical and genomic factors. Current Oncology Reports. 13: 37-41. PMID 21080116 DOI: 10.1007/S11912-010-0141-0  0.353
2011 Armstrong TS, Prabhu S, Aldape K, Hossan B, Kang S, Childress A, Tolentino L, Gilbert MR. A case of soft tissue metastasis from glioblastoma and review of the literature. Journal of Neuro-Oncology. 103: 167-72. PMID 20809248 DOI: 10.1007/S11060-010-0370-Y  0.453
2010 Armstrong TS, Vera-Bolanos E, Bekele BN, Aldape K, Gilbert MR. Adult ependymal tumors: prognosis and the M. D. Anderson Cancer Center experience. Neuro-Oncology. 12: 862-70. PMID 20511182 DOI: 10.1093/Neuonc/Noq009  0.529
2010 Liu Y, Shete S, Etzel CJ, Scheurer M, Alexiou G, Armstrong G, Tsavachidis S, Liang FW, Gilbert M, Aldape K, Armstrong T, Houlston R, Hosking F, Robertson L, Xiao Y, et al. Polymorphisms of LIG4, BTBD2, HMGA2, and RTEL1 genes involved in the double-strand break repair pathway predict glioblastoma survival. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 2467-74. PMID 20368557 DOI: 10.1200/Jco.2009.26.6213  0.361
2010 Armstrong TS, Gning I, Mendoza TR, Vera-Bolanos E, Gilbert MR, Rhines LD, Weinberg JS, Sanchez-Williams G, Levin V, Burton AW, Cleeland C. Reliability and validity of the M. D. Anderson Symptom Inventory-Spine Tumor Module. Journal of Neurosurgery. Spine. 12: 421-30. PMID 20367379 DOI: 10.3171/2009.10.Spine0943  0.495
2010 Armstrong TS, Cron SG, Bolanos EV, Gilbert MR, Kang DH. Risk factors for fatigue severity in primary brain tumor patients. Cancer. 116: 2707-15. PMID 20235192 DOI: 10.1002/Cncr.25018  0.503
2010 Armstrong TS, Choi S, Walker J, Gilbert MR. Seizure risk in brain tumor patients with conversion to generic levetiracetam. Journal of Neuro-Oncology. 98: 137-41. PMID 19936624 DOI: 10.1007/S11060-009-0066-3  0.672
2009 Armstrong TS, Cao Y, Scheurer ME, Vera-Bolaños E, Manning R, Okcu MF, Bondy M, Zhou R, Gilbert MR. Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factors. Neuro-Oncology. 11: 825-32. PMID 19179423 DOI: 10.1215/15228517-2008-120  0.36
2009 Armstrong TS, Gning I, Mendoza TR, Weinberg JS, Gilbert MR, Tortorice ML, Cleeland CS. Clinical utility of the MDASI-BT in patients with brain metastases. Journal of Pain and Symptom Management. 37: 331-40. PMID 18676120 DOI: 10.1016/J.Jpainsymman.2008.02.011  0.514
2008 Armstrong TS, Cao Y, Vera E, Scheurer ME, Manning R, Okcu MF, Bondy M, Gilbert MR. Pharmacoepidemiology of myelotoxicity (TOX) with temozolomide (TMZ) in malignant glioma patients. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 9548. PMID 27948137 DOI: 10.1200/Jco.2008.26.15_Suppl.9548  0.498
2008 Armstrong TS, Gilbert MR. Use of complementary and alternative medical therapy by patients with primary brain tumors. Current Neurology and Neuroscience Reports. 8: 264-8. PMID 18541122 DOI: 10.1007/S11910-008-0040-Z  0.504
2008 Tremont-Lukats I, Ratilal BO, Armstrong T, Gilbert MR. Antiepileptic drugs for preventing seizures in people with brain tumors Cochrane Database of Systematic Reviews. DOI: 10.1002/14651858.Cd004424.Pub2  0.404
2007 Gilbert MR, Armstrong TS. Management of patients with newly diagnosed malignant primary brain tumors with a focus on the evolving role of temozolomide. Therapeutics and Clinical Risk Management. 3: 1027-33. PMID 18516257  0.518
2007 Armstrong TS, Gilbert MR. Net clinical benefit: functional endpoints in brain tumor clinical trials. Current Oncology Reports. 9: 60-5. PMID 17164049 DOI: 10.1007/Bf02951427  0.472
2007 Armstrong TS, Mendoza T, Gning I, Smith ML, Gilbert MR, Weinberg J, Cleeland C. The utility of the MDASI-BT in assessing symptoms in patients with brain metastases Journal of Clinical Oncology. 25: 2052-2052. DOI: 10.1200/Jco.2007.25.18_Suppl.2052  0.519
2006 Armstrong T, Cohen MZ, Hess KR, Manning R, Lee EL, Tamayo G, Baumgartner K, Min SJ, Yung A, Gilbert M. Complementary and alternative medicine use and quality of life in patients with primary brain tumors. Journal of Pain and Symptom Management. 32: 148-54. PMID 16877182 DOI: 10.1016/J.Jpainsymman.2006.02.015  0.487
2006 Armstrong TS, Mendoza T, Gning I, Gring I, Coco C, Cohen MZ, Eriksen L, Hsu MA, Gilbert MR, Cleeland C. Validation of the M.D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT). Journal of Neuro-Oncology. 80: 27-35. PMID 16598415 DOI: 10.1007/S11060-006-9135-Z  0.52
2006 Armstrong TS, Mendoza T, Gning I, Coco C, Gilbert MR, Cleeland C, Cohen MZ, Eriksen L. Validation of the M. D. Anderson symptom inventory (MDASI-BT) Journal of Clinical Oncology. 24: 1546-1546. DOI: 10.1200/Jco.2006.24.18_Suppl.1546  0.45
2005 Armstrong T, Almadrones L, Gilbert MR. Chemotherapy-induced peripheral neuropathy Oncology Nursing Forum. 32: 305-311. PMID 15759068 DOI: 10.1188/05.Onf.305-311  0.37
2004 Armstrong TS, Cohen MZ, Weinberg J, Gilbert MR. Imaging techniques in neuro-oncology. Seminars in Oncology Nursing. 20: 231-9. PMID 15612599 DOI: 10.1016/J.Soncn.2004.07.003  0.429
2004 Armstrong TS, Gilbert MR. The treatment of neoplastic meningitis. Expert Opinion On Pharmacotherapy. 5: 1929-35. PMID 15330730 DOI: 10.1517/14656566.5.9.1929  0.39
2004 Armstrong T, Gilbert MR. Central nervous system toxicity from cancer treatment Current Oncology Reports. 6: 11-19. PMID 14664755 DOI: 10.1007/S11912-996-0004-X  0.427
2003 Armstrong TS, Kanusky JT, Gilbert MR. Seize the moment to learn about epilepsy in people with cancer. Clinical Journal of Oncology Nursing. 7: 163-9. PMID 12696212 DOI: 10.1188/03.Cjon.163-169  0.355
2002 Armstrong TS, Gilbert MR. Glial tumors--new approaches in chemotherapy. The Journal of Neuroscience Nursing : Journal of the American Association of Neuroscience Nurses. 34: 326-30. PMID 12506816 DOI: 10.1097/01376517-200212000-00007  0.443
2000 Armstrong TS, Gilbert MR. Metastatic brain tumors: diagnosis, treatment, and nursing interventions. Clinical Journal of Oncology Nursing. 4: 217-25. PMID 11111453  0.331
2000 Gilbert M, Armstrong T, Meyers C. Issues in assessing and interpreting quality of life in patients with malignant glioma Seminars in Oncology. 27: 20-26. PMID 10866346  0.335
2000 Armstrong T, Hancock C, Gilbert M. Symptom management of the patient with a brain tumor at the end of life Oncology Nursing Forum. 27: 616. PMID 10833685  0.33
1998 Armstrong TS, Gilbert MR. Chemotherapy of astrocytomas: an overview. Seminars in Oncology Nursing. 14: 18-25. PMID 9503511  0.311
Show low-probability matches.